Formulations of apremilast
Patent Information
- Application Number
- TW111119797
- Authority / Receiving Office
- TW · TW
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2021-05-28
- Filing Date
- 2022-05-27
- Publication Date
- 2026-11-01
- Estimated Expiration
- 2042-05-26
AI Technical Summary
Conventional oral dosage forms of apremilast do not maintain a clinically relevant drug concentration, as they often release the active ingredient too quickly, leading to inefficiencies and potential gastrointestinal issues.
The development of oral dosage forms comprising a tablet core with a drug layer containing apremilast and hypromellose acetate succinate (HPMCAS) as an amorphous solid dispersion, coated with an expandable layer and a coating layer, featuring a drug release hole, designed for once-daily administration.
The new dosage form provides sustained drug release, maintaining therapeutic levels of apremilast for 24 hours, reducing gastrointestinal symptoms and improving treatment efficacy.
Smart Images

Figure TWG2TB001918256_001 
Figure TWG2TB001918256_002 
Figure TWG2TB001918256_003
Abstract
Description
[Previous Technology]
[0001] Apremilast is a phosphodiesterase subtype IV ("PDE4") inhibitor and has been approved worldwide for the treatment of a variety of inflammation-related diseases. For example, in the United States, apremilast is approved for the treatment of adult patients with moderate to severe plaque psoriasis who are suitable for phototherapy or systemic therapy, for the treatment of adult patients with active psoriatic arthritis, and for the treatment of adult patients with oral ulcers associated with Behçet's disease. Apremilast is the first and only orally administered PDE4 inhibitor approved for the treatment of these inflammatory diseases. The recommended dose for adult patients with active PsA and psoriasis is 30 mg orally twice daily (BID) over 5 days, titrated to reduce gastrointestinal (GI) symptoms associated with initial therapy.
[0002] One goal in developing a drug is to provide a dosage form that can maintain a clinically or therapeutically relevant amount or concentration of the drug in a subject. In some cases, this may not be possible with conventional rapidly disintegrating tablets, as these tablets release the active ingredient contained therein in a single dose.
[0003] In view of the above, it is still necessary to provide an oral formulation of apremilast for clinically required drug exposure. [Summary of the Invention]
[0004] This disclosure provides oral dosage forms comprising a tablet core and a coating layer, the tablet core comprising (i) a drug layer comprising apremilast and hydroxypropyl methylcellulose acetate succinate (HPMCAS) in the form of an amorphous solid dispersion; and (ii) an expandable layer comprising one or more expandable polymers; the coating layer being disposed on the tablet core, wherein the surface of the oral dosage form comprises at least one drug release pore.
[0005] This disclosure further provides oral dosage forms comprising a tablet core and a coating layer, the tablet core comprising (i) a drug layer comprising 8-11 wt% aprestinum, 8-11 wt% hydroxypropyl methylcellulose acetate succinate (HPMCAS) based on the total weight of the tablet core, 2-7 wt% mannitol based on the total weight of the tablet core, 40-45 wt% polyethylene oxide based on the total weight of the tablet core, 0.1-0.5 wt% magnesium stearate based on the total weight of the tablet core, and 0.1-0.5 wt% colloidal silica based on the total weight of the tablet core, wherein the aprestinum and HPMCAs are in a solid dispersion; and (ii) an expandable layer comprising 18-25 wt% polyethylene oxide based on the total weight of the tablet core, 7-10 wt% microcrystalline cellulose based on the total weight of the tablet core, and 1.5-3.5 wt% colloidal silica based on the total weight of the tablet core. The tablet contains wt% sodium chloride, 0.01-0.2 wt% iron oxide and 0.05-0.3 wt% magnesium stearate based on the total weight of the tablet core; the coating layer is disposed on the tablet core and contains cellulose acetate and polyethylene glycol; wherein the oral dosage form surface contains at least one drug release pore.
[0006] This disclosure also provides oral dosage forms comprising a tablet core and a coating layer, the tablet core comprising (i) a drug layer comprising 10-15 wt% aprestinum, 10-15 wt% hydroxypropyl methylcellulose acetate succinate (HPMCAS) based on the total weight of the tablet core, 30-40 wt% polyethylene oxide based on the total weight of the tablet core, 2-8 wt% sodium chloride based on the total weight of the tablet core, 0.1-0.5 wt% magnesium stearate based on the total weight of the tablet core, and 0.1-0.5 wt% colloidal silica based on the total weight of the tablet core, wherein the aprestinum and HPMCAs are in a solid dispersion; and (ii) an expandable layer comprising 18-25 wt% polyethylene oxide based on the total weight of the tablet core, 7.5-10.0 wt% microcrystalline cellulose based on the total weight of the tablet core, and 2-4 wt% sodium chloride based on the total weight of the tablet core. The tablet contains wt% sodium chloride, 0.01-0.1 wt% iron oxide and 0.05-0.3 wt% magnesium stearate based on the total weight of the tablet core; the coating layer is disposed on the tablet core and comprises cellulose acetate and polyethylene glycol; wherein the oral dosage form surface comprises at least one drug release pore.
Implementation Method
[0020] This document provides oral dosage forms suitable for delivering a once-daily (QD) dose of apremilast. In some embodiments, the disclosed oral dosage forms are administered with food.
[0021] The oral dosage forms disclosed herein comprise a tablet core, a coating layer disposed on the tablet core, and at least one drug release orifice. In some embodiments, such oral dosage forms further comprise a base coat layer located between the tablet core and the coating layer. Tablet Core
[0022] The disclosed oral dosage form tablet core comprises i) a drug layer comprising apremilast and hydroxypropyl methylcellulose acetate succinate (HPMCAS) in an amorphous solid dispersion and ii) an expandable layer comprising one or more expandable polymers. Drug layer
[0023] The drug layer contains an appropriate amount of apremilast. Ideally, the drug layer contains an amount of apremilast suitable for providing once-daily delivery / administration of apremilast. If such oral dosage forms contain too little apremilast, then the dosage form will not deliver a clinically appropriate amount of apremilast and will not be effective at QD dosing. Conversely, if such oral dosage forms contain too much apremilast, then the dosage form is inefficient and too expensive in its use of apremilast. Furthermore, if too much or too little apremilast is present, then the biocompatibility of the dosage form and / or the flow and release of apremilast from the dosage form will be negatively affected. In some embodiments, the apremilast is present in an amount of 6-15 wt% of the tablet core. Examples of expected Apstec cores include, but are not limited to, the following weight percentages: 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9.0, 9.1, 9.2, 9.3, 9.4, 9.5, 9.6, 9.7, 9.8, 9.9, 10.0, 10.1, 10.2, 10.3, 10.4, 10.5, 10.6, 10.7, 10.8, 10.9, 11.0, 11 1, 11.2, 11.3, 11.4, 11.5, 11.6, 11.7, 11.8, 11.9, 12.0, 12.1, 12.2, 12.3, 12.4, 12.5, 12.6, 12.7, 12.8, 12.9, 13.0, 13.1, 13.2, 13.3, 13.4, 13.5 13.6, 13.7, 13.8, 13.9, 14.0, 14.1, 14.2, 14.3, 14.4, 14.5, 14.6, 14.7, 14.8, 14.9, 15.0, 15.1, 15.2, 15.3, 15.4, 15.5, 15.6, 15.7, 15.8, 15.9, and 16.0 wt%. In some embodiments, the apremierol is present in an amount of 8-11 wt% of the core. In various embodiments, the apremierol is present in an amount of 9.6 wt%, 10.2 wt%, or 12.5 wt% of the core.
[0024] In some embodiments, in conjunction with other embodiments above or below, the oral dosage forms contain a total amount of 25-100 mg. mg apremilast (e.g., 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100 mg apremilast). In some embodiments, in conjunction with other embodiments described above or below, the oral dosage forms comprise 25-30 mg of apremilast or 50-100 mg of apremilast (e.g., 50-60 mg or 65-85 mg of apremilast). In various embodiments, in conjunction with other embodiments described above or below, the oral dosage forms comprise 70, 75, or 80 mg of apremilast. In some embodiments, the oral dosage forms comprise 27.5 mg of apremilast, 55 mg of apremilast, 75 mg of apremilast, or 100 mg of apremilast.
[0025] In addition to apremilast, this drug layer also contains HPMCAS. As used herein, HPMCAS refers to a family of cellulose derivatives that can have (1) two ether substituents (methyl and / or 2-hydroxypropyl) and (2) two ester substituents (acetyl and / or succinyl). The chemical name for HPMCAS is also O-(2-hydroxypropyl)-O-methyl-cellulose acetate succinate. The degree of substitution of each of the four general types just mentioned can vary over a wide range to affect the chemical and physical properties of the polymer. This versatility of HPMCAS allows for the optimization of its structure to achieve good performance for a specific drug purpose. HPMCAS can be synthesized or commercially available. Three examples of commercially available HPMCAS include Shin-Etsu AQOAT®-LF, Shin-Etsu AQOAT®-MF, and Shin-Etsu AQOAT®-HF. All three polymers were manufactured by Shin-Etsu Chemical Co., Ltd., Tokyo, Japan. In some embodiments, HPMCAS are classified as L grades (e.g., HPMCAS-LF, HPMCAS-LG, or HPMCAS-LMP), where it should be understood that the acetyl and succinic acid content differs among L, M, and H grades of HPMCAS. L, M, and H grades also refer to the pH at which the polymer dissolves (L = low pH ≥ 5.5, M = medium pH ≥ 6.0, and H = high pH ≥ 6.5). LF, LG, and LMP grades refer to different average particle sizes (F grade: viscous fine powder - 5 µm, MP grade: medium particle size - 200 µm, G grade: free-flowing particles - 1000 µm).
[0026] HPMCAS has any suitable molecular weight. In some embodiments, the average weight-average molecular weight of HPMCAS ranges from 10,000 to 1,000,000 Daltons (e.g., 10,000 to 400,000 Daltons or 55,000 to 115,000 Daltons, as determined using polyethylene oxide standards). Note that molecular weight may be expressed in Daltons (Da) or g / mol herein, and these are used interchangeably throughout the document. Molecular weight ranges may also vary based on the degree of substitution (e.g., the presence of acetyl and / or succinyl groups). For example, in various embodiments, in combination with other embodiments above or below, the average weight-average molecular weight of HPMCAS is approximately 15,000 to 20,000 Daltons, such as 15,000, 16,000, 17,000, 18,000, 19,000, or 20,000 Daltons. In some embodiments, the average weight-average molecular weight of HPMCAS is 17,700, 17,900, 18,800, 18,900, 20,400, or 21,200 Daltons. In some embodiments, in combination with other embodiments above or below, the number-average molecular weight is approximately 13,000 Daltons.
[0027] The drug layer contains a suitable amount of HPMCAS. If the drug layer contains too little or too much HPMCAS, the amorphous solid dispersion may not have the desired release characteristics. In some embodiments, HPMCAS is 6-15% of the tablet core. The following quantities (wt%) are present (e.g., the following cores): 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9.0, 9.1, 9.2, 9.3, 9.4, 9.5, 9.6, 9.7, 9.8, 9.9, 10.0, 10.1, 10.2, 10.3, 10.4, 10.5, 10.6, 10.7, 10.8, 10.9, 11.0, 11.1, 11.2, 11.3, 11.4, 11.5, 11.6, 11.7, 11.8, 11.9, 12.0, 12.1, 12.2, 12.3, 12.4, 12.5, 12.6, 12.7, 12.8, 12.9, 13.0, 13.1, 13.2, 13.3, 13.4, 13.5, 13.6, 13.7, 13.8, 13.9, 14.0, 14.1, 14.2, 14.3, 14.4, 14.5, 14.6, 14.7, 14.8, 14.9, or 15.0 wt%. In some embodiments, HPMCAS is present in an amount of 8-11 wt% of the wafer core. In various embodiments, HPMCAS is present in amounts of 9.6 wt%, 10.2 wt%, or 12.5 wt% of the chip core.
[0028] In some embodiments, in conjunction with other embodiments above or below, the oral dosage forms contain a total amount of 25-100 mg. HPMCAS mg (e.g., 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99 or 100 mg HPMCAS). In some embodiments, in conjunction with other embodiments described above or below, the oral dosage forms comprise 65-85 mg HPMCAS. In various embodiments, in conjunction with other embodiments described above or below, the oral dosage forms comprise 25-30 mg HPMCAS or 50-100 mg HPMCAS (e.g., 50-60 mg or 65-85 mg HPMCAS). In various embodiments, in conjunction with other embodiments described above or below, the oral dosage forms comprise 70, 75, or 80 mg HPMCAS. In some embodiments, the oral dosage forms comprise 27.5 mg HPMCAS, 55 mg HPMCAS, 75 mg HPMCAS, or 100 mg HPMCAS.
[0029] In various embodiments, the Apstar and HPMCAS are present in the core at a weight ratio of 40:60 to 60:40. For example, in some embodiments, the weight ratio of Apstar:HPMCAS in the core is: 40:60, 41:59, 42:58, 43:57, 44:56, 45:55, 46:56, 47:53, 48:52, 49:51, 50:50, 51:49, 52:48, 53:47, 54:46, 55:45, 56:44, 57:43, 58:42, 59:41 or 60:40. In some embodiments, the apremilast and HPMCAS are present in the core at a weight ratio of 45:55 to 55:45. In various embodiments, the apremilast and HPMCAS are present in the core at a weight ratio of 48:52 to 52:48. In some embodiments, the apremilast and HPMCAS are present in the core at a weight ratio of 50:50. Amorphous solid dispersion
[0030] Apremilast and HPMCAS are present in the tablet core as amorphous solid dispersions. Without wishing to be limited to any particular theory, it is believed that the amorphous solid dispersion provides improved bioavailability of apremilast due to, for example, 1) improved drug dispersion, thereby preventing or delaying the rate of solid-state crystallization, 2) improved in vivo dissolution, thereby facilitating drug release in the gastrointestinal tract, and 3) inhibition of precipitation or crystallization of water-soluble drugs. Apremilast needs to remain amorphous in the composition disclosed herein because small amounts (e.g., 1.5 wt% or less) of crystalline apremilast have been found to result in slower dissolution of the solid dispersion.
[0031] In some embodiments, in conjunction with other embodiments above or below, the amorphous solid dispersion system is spray-dried. It has been found that Apstec's spray-dried solid dispersions (SDDs) in HPMCAS offer unexpectedly good solubility and improved ease of formulation. As understood, spray drying refers to a process involving the breakdown of a liquid mixture into small droplets (atomization) and the rapid removal of solvent from the mixture in a container, wherein there is a strong driving force in the container for the solvent to evaporate from the droplets. The strong driving force for solvent evaporation is typically provided by maintaining the solvent partial pressure in the spray drying apparatus at a solvent vapor pressure well below the temperature of the dried droplets. This is achieved by: (1) maintaining the pressure in the spray drying apparatus at a partial vacuum (e.g., 0.01-0.50 atm); (2) mixing the droplets with a warm drying gas; or (3) both. For example, the solution of the drug and HPMCAS in acetone can be appropriately spray-dried by connecting the outlet to a vacuum pump to spray a solution at 50°C (the vapor pressure of acetone at 50°C is approximately 0.8 atm) into a chamber maintained at a total pressure of 0.01–0.2 atm. Alternatively, the acetone solution can be sprayed into the chamber, where it is mixed with nitrogen or other inert gases at a temperature of 80–180°C and a pressure of 1.0–1.2 atm.
[0032] Typically, the temperature and flow rate of the drying gas are chosen such that the HPMCAS / drug solution droplets are sufficiently dry to be essentially solid by the time they reach the device wall, thus forming a fine powder and not adhering to the device wall. The actual time required to achieve this level of dryness depends on the droplet size. Droplet diameters are typically between 1 μm and 500 μm, more typically 5 to 100 μm. The large surface area ratio of the droplets and the strong driving force of solvent evaporation result in actual drying times of a few seconds or less. This rapid drying is important for maintaining a uniform, homogeneous composition of the particles rather than separating them into drug-rich and polymer-rich phases. Such dispersions with homogeneous compositions can be considered solid solutions and may be supersaturated in the drug. Such homogeneous dispersions are preferred because they can achieve higher maximum supersaturated concentrations (MSSCs) when dispensing large quantities of drug, relative to dispersions in which at least a portion of the drug exists as a drug-rich amorphous or crystalline phase. The curing time should be less than 20 seconds, preferably less than 5 seconds, and even more preferably less than 2 seconds. Typically, to achieve this rapid curing of the drug / polymer solution, the droplet size formed during spray drying is preferably less than 100 μm in diameter, more preferably less than 50 μm, and even more preferably less than 25 μm. The resulting solid particles are typically less than 100 μm in diameter, preferably less than 50 μm, and even more preferably less than 25 μm.
[0033] After curing, the solid powder can remain in the spray drying chamber for 5-50 seconds to further evaporate the solvent from the solid powder. When the solid dispersion leaves the dryer, its final solvent content should be low, as this reduces the flowability of drug molecules in the dispersion, thereby improving its stability. Typically, the residual solvent content of the dispersion should be less than 10 wt%, preferably less than 2 wt%.
[0034] The dispersion can then be post-processed using methods known in the art (e.g., rolling, fluid bed coagulation, or spraying) to prepare a dispersion for feeding. Spray drying methods and spray drying equipment are generally described in, for example, Chemical Engineers' Handbook, 6th edition (edited by RH Perry, DW Green, JO Maloney), McGraw-Hill Book Co., 1984, pp. 20-54 to 20-57. Marshall ("Atomization and Spray-Drying", Chem. Eng. Prog. Monogr. Series, 50
[1954] 2).
[0035] In some embodiments, the solution for spray drying to form the HPMCAS / aprast dispersion contains only apresin and HPMCAS in the solvent. In some embodiments, the ratio of apresin to HPMCAS in the solution is 0.2-1.2 : 1-100 or 0.4-1.2 : 1-20. In some embodiments, the ratio of apresin to HPMCAS in the spray-dried solution is 1.2-0.8 : 1. The solvent suitable for spray drying can be any organic compound in which apresin and HPMCAS are mutually soluble. Preferably, the solvent is also volatile and has a boiling point of 150°C or lower. In some embodiments, the solvent includes alcohols, such as methanol, ethanol, n-propanol, isopropanol, and butanol; ketones, such as acetone, methyl ethyl ketone, and methyl isobutyl ketone; esters, such as ethyl acetate and propyl acetate; and various other solvents, such as acetonitrile, dichloromethane, toluene, and 1,1,1-trichloroethane. Solvents with low volatility, such as dimethylacetamide or dimethyl sulfoxide, can also be used. Mixtures of solvents, or mixtures with water, can also be used, provided that the polymer and HPMCAS are sufficiently soluble to make the spray drying process feasible. In some embodiments, the solvent includes acetone.
[0036] In some embodiments, the spray-drying solution and the resulting dispersion may also contain various excipients / additives, as described herein, that contribute to the stability, solubility, tableting, or processing of the dispersion. Examples of such additives in some embodiments include: surfactants, pH-controlling substances (e.g., acids, bases, buffers), diluents / fillers, disintegrants, lubricants, or binders. When present, such excipients / additives may be added directly to the spray-drying solution, causing the additive to dissolve or suspend in the solution as a slurry. Alternatively, such additives may be added after the spray-drying process to aid in the formation of the final dosage form.
[0037] Water-soluble polymer
[0038] In some embodiments, the drug layer comprises a water-soluble polymer. When present, the water-soluble polymer in the drug layer is any suitable water-soluble polymer. Suitable water-soluble polymers include, for example, polyethylene oxide and combinations thereof. In various embodiments, the water-soluble polymer is polyethylene oxide.
[0039] The water-soluble polymer in the drug layer has a suitable molecular weight. For example, in embodiments where the water-soluble polymer in the drug layer is polyethylene oxide (PEO), the polyethylene oxide has an average molecular weight of 200,000 Da or higher. In some embodiments, the polyethylene oxide has an average molecular weight of 200,000 Da to 300,000 Da (e.g., 200,000 and / or 300,000 Da) and / or 600,000 Da. Some embodiments have been found to exhibit improved stability where the drug layer comprises polyethylene oxide having more than one average molecular weight (e.g., a mixture of polyethylene oxides). For example, in embodiments where the drug layer comprises a mixture of polyethylene oxides with molecular weights of 200,000 Da and 300,000 Da, the amount of crystallized apremilast formed during some stability studies (e.g., accelerated stability studies) is less than that of polyethylene oxide containing only one low molecular weight (e.g., 200,000 Da). In some cases, the polyethylene oxide is a mixture of 200 kDa PEO and 300 kDa PEO in a 1:1 weight ratio. In some cases, the polyethylene oxide is a mixture of 200 kDa PEO and 300 kDa PEO in a 20:80 weight ratio. In some cases, the polyethylene oxide is 300 kDa PEO. Certain embodiments containing high molecular weight (e.g., at least 300,000 Da) polyethylene oxide and further containing a penetrant (e.g., sodium chloride) in the drug layer can provide improved dissolution, hysteresis time (e.g., shortened hysteresis time), and stability.
[0040] Exemplary polyethylene oxide systems suitable for pharmaceutical layers are the POLYOX WSR series of PEO, commercially available from DuPont in Midland, MI, including POLYOX® WSR N80, POLYOX® WSR N750 and POLYOX® WSR 205. POLYOX® WSR N80 (commercially available from DuPont in Midland, Michigan) has the following physical properties: MW: 200,000 Da; viscosity: 65-115 cP; silicon dioxide content: 0.8-3.0 wt%; particle size: 10 mesh: 100 min; particle size: 20 mesh: 96-100 min. POLYOX® WSR N750 (commercially available from DuPont in Midland, Michigan) has the following physical properties: MW: 300,000 Da; viscosity: 600-1,200 cP; silicon dioxide content: 0.8-3.0 wt%; particle size: 10 mesh: 100 min; particle size: 20 mesh: 96-100 min. 205 (available from DuPont in Midland, Michigan) has the following physical properties: MW: 600,000 Da; viscosity: 6,800-8,800 cP; and silicon dioxide content: 0.8-3.0 wt%.
[0041] The water-soluble polymer is present in a suitable amount. For example, in some embodiments, the water-soluble polymer is present in an amount of 30-55 wt% (e.g., 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, or 55 wt% of the core). In some embodiments, the water-soluble polymer is present in an amount of 30-55, 35-50, 35-45, 35-40, 40-55, 40-50, 45-55, or 45-50 wt% of the core. In some embodiments, in conjunction with other embodiments described above or below, the water-soluble polymer (e.g., polyethylene oxide) is present at 34.3 wt%, 35 wt%, 37.6 wt%, or 42.7 wt% of the tablet core. In various embodiments, in conjunction with other embodiments described above or below, the water-soluble polymer and apremilast are present in the drug layer at a weight ratio of 2-6:1. For example, in various embodiments, the weight ratio of the water-soluble polymer to apremilast in the drug layer is 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, or 6.0:1. In some embodiments, in conjunction with other embodiments above or below, the weight ratio of the water-soluble polymer to apremilast in the drug layer is 2.7, 2.8, 3.0, 3.7, 4.2, or 5.1:1.
[0042] In some embodiments, the oral dosage forms contain 100 mg or more of polyethylene oxide in the drug layer, for example, 105, 110, 115, 120, or 125 mg of polyethylene oxide in the drug layer. In some embodiments, the oral dosage forms contain 200 mg or more of polyethylene oxide in the drug layer, for example, 205, 210, 215, 220, 225, 230, 235, 240, 245, 250, 255, 260, 265, 270, 275, 280, 285, or 290 mg of polyethylene oxide in the drug layer. In some embodiments, the oral dosage forms contain 300 mg or more of polyethylene oxide in the drug layer, for example, 305, 310, 315, 320, 325, 330, 335, 340, 345, 350, 355, or 360 mg of polyethylene oxide in the drug layer. In some embodiments, in conjunction with other embodiments above or below, the oral dosage forms disclosed herein contain 115.6 mg, 206 mg, 230.9 mg, 274.6 mg, 301.4 mg, 307.2 mg, 314.8 mg, 332.8 mg, or 358.4 mg of polyethylene oxide in the drug layer. Diluents, lubricants, and slip agents.
[0043] In some embodiments, in conjunction with other embodiments above or below, the drug layer comprises a diluent. The diluent may be extragranular (EG) and / or intragranular (IG). In some embodiments, the diluent is intragranular (IG). In some embodiments, the drug layer comprises both intragranular and extragranular diluents. The diluent is present in any suitable amount. In some embodiments, in conjunction with other embodiments above or below, the diluent is present in an amount of 2-7 wt% of the tablet core (e.g., 2, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, or 7.0 wt% of the tablet core). In some embodiments, the diluent is present in an amount of 3.0 wt% or 4.8 wt% of the tablet core.
[0044] Non-limiting examples of diluents include lactose, sucrose, glucose, mannitol, sorbitol, calcium phosphate, calcium carbonate, microcrystalline cellulose, and cellulose. Mannitol is an exemplary suitable diluent in this pharmaceutical layer. In embodiments where the diluent comprises mannitol, the pharmaceutical layer typically contains 5-60 mg of mannitol (e.g., 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, or 60 mg of mannitol). For example, in various embodiments, in conjunction with other embodiments above or below, the pharmaceutical layer contains 8.1 mg, 16.2 mg, 22.1 mg, 25.0 mg, 48.0 mg, 52.0 mg, or 56.0 mg of mannitol. In some embodiments, the drug layer comprises 12.3 mg mannitol (IG) and 9.8 mg mannitol (EG), 9.0 mg mannitol (IG) and 7.2 mg mannitol (EG), 4.5 mg mannitol (IG) and 3.6 mg mannitol (EG), or 25 mg mannitol (IG) and 25 mg mannitol (EG). In some embodiments, the drug layer comprises 50 mg mannitol (EG). In some embodiments that simultaneously contain IG mannitol and EG mannitol, 55%-57% of the total mannitol present is intraparticle and 43%-45% of the total mannitol present is extraparticle.
[0045] In some embodiments, in conjunction with other embodiments above or below, the drug layer comprises a lubricant. The lubricant may be extragranular (EG) and / or intragranular (IG). In some embodiments, the lubricant is intragranular (IG). In some embodiments, the drug layer comprises both intragranular and extragranular lubricants. The lubricant is present in any suitable amount. In some embodiments, in conjunction with other embodiments above or below, for example, the lubricant is present in an amount of 0.05-0.50 wt% of the tablet core (e.g., 0.05, 0.10, 0.15, 0.2, 0.25, 0.30, 0.35, 0.40, 0.45, or 0.50 wt% of the tablet core). In some embodiments, in conjunction with other embodiments above or below, the lubricant (e.g., magnesium stearate) is present in an amount of 0.25 wt%, 0.31 wt%, 0.33 wt%, or 0.37 wt% of the tablet core.
[0046] Examples of lubricants include magnesium stearate, talc, starch, and cellulose. An exemplary suitable lubricant is magnesium stearate. In embodiments where the lubricant comprises magnesium stearate, the pharmaceutical layer typically comprises 1-5 mg of magnesium stearate (e.g., 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, or 5.0 mg of magnesium stearate). For example, in various embodiments, in conjunction with other embodiments above or below, the pharmaceutical layer comprises 1.0, 1.7, 2.0, 2.4, 2.5, 2.6, 2.7, or 2.8 mg of magnesium stearate. In some embodiments, the pharmaceutical layer comprises 0.5, 0.9, 1.0, 1.2, 1.3, or 1.4 mg of magnesium stearate (IG) and 0.5, 1.0, 1.2, 1.3, or 1.4 mg of magnesium stearate (EG).
[0047] In some embodiments, in conjunction with other embodiments above or below, the pharmaceutical layer comprises a lubricant. In some embodiments, the lubricant is ex-particle. The lubricant is present in any suitable amount. In some embodiments, in conjunction with other embodiments above or below, for example, the lubricant is present in an amount of 0.05-0.50 wt% (e.g., 0.05, 0.10, 0.15, 0.2, 0.25, 0.30, 0.35, 0.40, 0.45, or 0.50 wt% of the core material). In some embodiments, in conjunction with other embodiments above or below, the lubricant (e.g., colloidal silicon dioxide) is present in an amount of 0.25 wt%, 0.33 wt%, 0.34 wt%, or 0.37 wt% of the core material.
[0048] Examples of slip agents include silica, magnesium stearate, and talc. A suitable, exemplary slip agent is silica (e.g., colloidal silica). In embodiments where the slip agent comprises silica, the pharmaceutical layer typically contains 0.5-5 mg of silica (e.g., 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, or 5.0 mg of silica). For example, in various embodiments, in conjunction with other embodiments above or below, the pharmaceutical layer contains 0.9, 1.8, 2.0, 2.4, 2.5, 2.6, 2.7, or 2.8 mg of silica.
[0049] In some embodiments, the drug layer of the disclosed oral dosage form further comprises a permeabilizer. When present, the permeabilizer of the drug layer can be any suitable permeabilizer. Non-limiting examples of permeabilizers include sugars and sodium chloride. In some embodiments, in conjunction with other embodiments above or below, the permeabilizer of the drug layer comprises sodium chloride. The permeabilizer of the drug layer is present in any suitable amount. In some embodiments, in conjunction with other embodiments above or below, the drug layer comprises 2-12 wt% permeabilizer (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 wt% permeabilizer). In some embodiments, the drug layer comprises 5 wt%, 7.7 wt%, or 10 wt% permeabilizer (e.g., sodium chloride). Depending on the dosage form's dose intensity, the drug layer contains 15-60 mg of penetrant (e.g., 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, or 60 mg penetrant). In some embodiments, the drug layer contains 18.0, 26.7, 40, or 53.3 wt% penetrant (e.g., sodium chloride). In some embodiments, the penetrant of the drug layer (e.g., sodium chloride) is present in an amount of 3-8 wt% (e.g., 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, or 8.0 wt%) of the core. In some embodiments, the permeabilizer (e.g., sodium chloride) of the drug layer is present in an amount of 3.3 wt%, 5.1 wt%, or 6.7 wt% of the core. Expandable layer
[0050] The expandable layer comprises one or more expandable polymers. Therefore, the expandable layer expands upon contact with water, and this expansion generates pressure that causes the drug to be released from the drug layer through at least one drug release pore of the dosage form. In some embodiments, in conjunction with other embodiments above or below, the drug layer and the expandable layer are present in the tablet core at a weight ratio of 2:1.
[0051] The expandable polymer can be any suitable expandable polymer. In some embodiments, the expandable polymer comprises polyethylene oxide. An exemplary polyethylene oxide system suitable for the expandable layer is, for example, POLYOX® WSR Coagulant (commercially available from DuPont, Midland, Michigan), which has the following physical properties: MW: 5,000,000 Da; viscosity: 5,500-7,500 cP; and silicon dioxide: 0.8-3.0 wt%. The polyethylene oxide of the expandable layer typically has a higher molecular weight (e.g., 5,000,000 Da) than the polyethylene oxide of the pharmaceutical layer.
[0052] The expandable polymer is present in any suitable amount. Typically, the expandable polymer (e.g., polyethylene oxide) is present in an amount of 50-70 wt% (e.g., 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, or 70 wt%) of the expandable layer. In some embodiments, in conjunction with other embodiments above or below, the expandable polymer is present in an amount of 50-70 wt%, 55-70 wt%, or 55-65 wt% of the expandable layer. In some embodiments, the expandable polymer is present in an amount of 64.8 wt%, 64.9 wt%, or 65 wt% of the expandable layer. Depending on the dosage strength of the formulation, the expandable polymer is present in the expandable layer in amounts of 50-75 mg, 100-130 mg, and 150-200 mg. In some embodiments, the expandable polymer (e.g., polyethylene oxide) is present in the expandable layer in amounts of 58.6 mg, 117.0 mg, 129.8 mg, 159.6 mg, or 173.1 mg. In some embodiments, in conjunction with other embodiments described above or below, the expandable polymer is present in an amount of 15-25 wt% (e.g., 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 wt% of the tablet core). In some embodiments, the expandable polymer constitutes 21.6 wt% or 22 wt% of the tablet core.
[0053] In some embodiments, the expandable layer further comprises one or more of a penetrant, a diluent, a lubricant, and a colorant.
[0054] The permeabilizer of the expandable layer may be any suitable permeabilizer as described herein. Non-limiting examples of permeabilizers include sugar and sodium chloride. In some embodiments, in conjunction with other embodiments above or below, the permeabilizer comprises sodium chloride. The permeabilizer is present in any suitable amount. In some embodiments, in conjunction with other embodiments above or below, the expandable layer comprises 5-15 wt% permeabilizer (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 wt% permeabilizer). In some embodiments, the expandable layer comprises 5-10 wt%, 5-7 wt%, 8-12 wt%, or 8-10 wt% permeabilizer. In some embodiments, the expandable layer comprises 8.4 wt%, 8.5 wt%, 8.6 wt%, 9.1 wt%, or 9.8 wt% permeabilizer. Depending on the dosage strength of the formulation, the expandable layer contains 5-25 mg of penetrant (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 mg of penetrant). In some embodiments, the expandable layer contains 7.8 mg, 15.5 mg, 17.2 mg, 20.6 mg, 21.1 mg, 22.4 mg, 22.9 mg, or 24.1 mg of penetrant (e.g., sodium chloride). For example, in some embodiments, the penetrant (e.g., sodium chloride) is present in an amount of 1.5-3.5 wt% of the total core (e.g., 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, or 3.5 wt% of the core). In some embodiments, the penetrant (e.g., sodium chloride) is present in an amount of 2.80, 2.85, 2.90, or 2.95 wt% of the core.
[0055] The diluent for the expandable layer may be any suitable diluent as described herein. An exemplary suitable diluent in the expandable layer is microcrystalline cellulose. In some embodiments, in conjunction with other embodiments above or below, the diluent comprises sodium chloride. The diluent is present in any suitable amount. In some embodiments, the diluent (e.g., microcrystalline cellulose) is present in an amount of 20-35 wt% (e.g., 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 35 wt%) of the expandable layer. In some embodiments, the diluent is present in an amount of 25.2 wt%, 25.8 wt%, 27.3 wt%, or 29.4 wt% of the expandable layer. In some embodiments, the diluent is present in an amount of 7-10 wt% of the core (e.g., 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9.0, 9.1, 9.2, 9.3, 9.4, 9.5, 9.6, 9.7, 9.8, 9.9, or 10.0 wt%).
[0056] The lubricant for the expandable layer may be any suitable lubricant as described herein. An exemplary suitable lubricant in the expandable layer is magnesium stearate. The lubricant is present in any suitable amount. In some embodiments, the lubricant is present in an amount of 0.3-1 wt% (e.g., 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0 wt%) of the expandable layer. In some embodiments, in conjunction with other embodiments above or below, the lubricant is present in an amount of 0.5 wt% or 0.6 wt% of the expandable layer. In some embodiments, in conjunction with other embodiments above or below, for example, the lubricant of the expandable layer is present in an amount of 0.05-0.50 wt% (e.g., 0.05, 0.10, 0.15, 0.2, 0.25, 0.30, 0.35, 0.40, 0.45, or 0.50 wt%) of the core. Depending on the dosage strength of the dosage form, in various embodiments, the expandable layer comprises 0.5, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, or 1.5 mg of magnesium stearate.
[0057] The colorant can be any suitable colorant. An exemplary suitable colorant is iron oxide red. The colorant is present in any suitable amount. In some embodiments, in conjunction with other embodiments above or below, for example, the colorant of the expandable layer (e.g., iron oxide red) is present in an amount of 0.05-0.50 wt% (e.g., 0.05, 0.10, 0.15, 0.2, 0.25, 0.30, 0.35, 0.40, 0.45, or 0.50 wt% of the core material. In some embodiments, the colorant is present in an amount of 0.05, 0.06, 0.07, 0.08, 0.09, or 0.10 wt% of the core material. In various embodiments, in conjunction with other embodiments above or below, the expandable layer contains 0.2 mg, 0.4 mg, or 0.5 mg of the colorant (e.g., iron oxide red). Coating layer
[0058] The oral dosage form disclosed herein includes a coating layer disposed on the tablet core. In some embodiments, the coating layer is present in an amount of 6.5-8.5 wt% based on the total weight of the oral dosage form. In some embodiments, the coating layer is present in an amount of 7.5 wt% based on the total weight of the oral dosage form. In some embodiments, the coating layer comprises cellulose acetate (CA) and polyethylene glycol (PEG). In various embodiments, the PEG has an average molecular weight of 3,000-4,000 Da, for example 3,000-3,700 Da or 3,350 Da.
[0059] Cellulose acetate and PEG are present in any suitable amounts. In some embodiments, the coating layer contains 10-80 mg CA (e.g., 10, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, or 80 mg CA). In some embodiments, the coating layer contains 15.2, 30.3, 36.3, 37.4, 40.3, 41.3, 49.6, 72.0, and 74.9 mg CA. In some embodiments, in combination with other embodiments above or below, the coating layer contains 3.8, 7.6, 9.1, 9.4, 10.1, 10.3, 12.4, 18.0, or 18.7 mg PEG. In some embodiments, CA and PEG are present in a CA:PEG weight ratio of 3.5-4.5:1. For example, in some embodiments, the weight ratio of CA to PEG in the coating layer is 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4, or 4.5. In some embodiments, CA and PEG are present in a CA:PEG weight ratio of 4:1. Base Coating Layer
[0060] In some embodiments, the disclosed oral dosage form further comprises a base coat layer located between the tablet core and the coating layer. In some embodiments, the base coat layer comprises hydroxypropyl methylcellulose (HPMC).
[0061] When present, the base coat is present in any suitable amount. In some embodiments, the base coat is present in an amount of 2-4 wt% of the oral dosage form (e.g., 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, or 4.0 wt% of the oral dosage form). In some embodiments, the base coat is present in an amount of 2.3 wt% of the oral dosage form. In some embodiments, the base coat is present in an amount of 3.4 wt% of the oral dosage form.
[0062] In some embodiments, the coating layer further comprises a colored coating layer. The colored coating layer comprises one or more suitable colorants. An exemplary suitable colorant is Opadry® II colorant, commercially available from Colorcon, Inc. (Harleysville, PA). The colored coating layer is present in a suitable amount. In some embodiments, the colored coating layer is present in an amount of 3-5 wt% (3.0, 3.5, 4.0, 4.5, 5.0 wt%) of the oral dosage form. In some embodiments, the colored coating layer is present in an amount of 3.4 wt% of the oral dosage form. Drug release orifice
[0063] The oral dosage forms disclosed herein include at least one drug release orifice. In some embodiments, the drug release orifice is formed by drilling the oral dosage form. Typically, the size of the drug release orifice ranges from 600 µm to 1.5 mm. In some embodiments, the oral dosage form is drilled using a 900 μm drill bit. In some embodiments, the oral dosage form is drilled using a 1600 μm drill bit. In some embodiments, the drug release orifice has a size of 1.2 mm.
[0064] In some embodiments, this disclosure provides oral dosage forms comprising a tablet core and a coating layer. The tablet core comprises (i) a drug layer comprising 8-11 wt% aprestinum, 8-11 wt% hydroxypropyl methylcellulose acetate succinate (HPMCAS) based on the total weight of the tablet core, 2-7 wt% mannitol based on the total weight of the tablet core, 40-45 wt% polyethylene oxide based on the total weight of the tablet core, 0.1-0.5 wt% magnesium stearate based on the total weight of the tablet core, and 0.1-0.5 wt% colloidal silica based on the total weight of the tablet core, wherein the aprestinum and HPMCAs are in a solid dispersion; and (ii) an expandable layer comprising 18-25 wt% polyethylene oxide based on the total weight of the tablet core, 7-10 wt% microcrystalline cellulose based on the total weight of the tablet core, and 1.5-3.5 wt% silica based on the total weight of the tablet core. The tablet contains wt% sodium chloride, 0.01-0.2 wt% iron oxide and 0.05-0.3 wt% magnesium stearate based on the total weight of the tablet core; the coating layer is disposed on the tablet core and contains cellulose acetate and polyethylene glycol; wherein the oral dosage form surface contains at least one drug release pore.
[0065] In some embodiments, this disclosure provides oral dosage forms comprising a tablet core and a coating layer, the tablet core comprising (i) a drug layer comprising 75 mg apremilast, 75 mg hydroxypropyl methylcellulose acetate succinate (HPMCAS), 22.1 mg mannitol, 314.8 mg polyethylene oxide, 2.4 mg magnesium stearate, and 2.5 mg colloidal silica, wherein the apremilast and HPMCAS are in a solid dispersion; and (ii) an expandable layer comprising 159.6 mg polyethylene oxide, 63.4 mg microcrystalline cellulose, 21.1 mg sodium chloride, 0.5 mg iron oxide, and 1.2 mg magnesium stearate; the coating layer is disposed on the tablet core and comprises cellulose acetate and polyethylene glycol; wherein the surface of the oral dosage form comprises at least one drug release pore.
[0066] In some embodiments, this disclosure provides oral dosage forms comprising a tablet core and a coating layer, the tablet core comprising (i) a drug layer comprising 55 mg apremilast, 55 mg hydroxypropyl methylcellulose acetate succinate (HPMCAS), 16.2 mg mannitol, 230.9 mg polyethylene oxide, 1.7 mg magnesium stearate, and 1.8 mg colloidal silica, wherein the apremilast and HPMCAS are in a solid dispersion; and (ii) an expandable layer comprising 117 mg polyethylene oxide, 46.5 mg microcrystalline cellulose, 15.5 mg sodium chloride, 0.4 mg iron oxide, and 0.9 mg magnesium stearate; the coating layer is disposed on the tablet core and comprises cellulose acetate and polyethylene glycol; wherein the surface of the oral dosage form comprises at least one drug release pore.
[0067] In some embodiments, this disclosure provides oral dosage forms comprising a tablet core and a coating layer, the tablet core comprising (i) a drug layer comprising 27.5 mg apremilast, 27.5 mg hydroxypropyl methylcellulose acetate succinate (HPMCAS), 8.1 mg mannitol, 115.6 mg polyethylene oxide, 1.0 mg magnesium stearate, and 0.9 mg colloidal silica, wherein the apremilast and HPMCAS are in a solid dispersion; and (ii) an expandable layer comprising 58.6 mg polyethylene oxide, 23.3 mg microcrystalline cellulose, 7.8 mg sodium chloride, 0.2 mg iron oxide, and 0.5 mg magnesium stearate; the coating layer is disposed on the tablet core and comprises cellulose acetate and polyethylene glycol; wherein the surface of the oral dosage form comprises at least one drug release pore.
[0068] In some embodiments, this disclosure provides oral dosage forms comprising a tablet core and a coating layer, the tablet core comprising (i) a drug layer comprising 10-15 wt% aprestinum, 10-15 wt% hydroxypropyl methylcellulose acetate succinate (HPMCAS) based on the total weight of the tablet core, 30-40 wt% polyethylene oxide based on the total weight of the tablet core, 2-8 wt% sodium chloride based on the total weight of the tablet core, 0.1-0.5 wt% magnesium stearate based on the total weight of the tablet core, and 0.1-0.5 wt% colloidal silica based on the total weight of the tablet core, wherein the aprestinum and HPMCAs are in a solid dispersion; and (ii) an expandable layer comprising 18-25 wt% polyethylene oxide based on the total weight of the tablet core, 7.5-10.0 wt% microcrystalline cellulose based on the total weight of the tablet core, and 2-4 wt% sodium chloride based on the total weight of the tablet core. The tablet contains wt% sodium chloride, 0.01-0.1 wt% iron oxide and 0.05-0.3 wt% magnesium stearate based on the total weight of the tablet core; the coating layer is disposed on the tablet core and comprises cellulose acetate and polyethylene glycol; wherein the oral dosage form surface comprises at least one drug release pore.
[0069] In some embodiments, this disclosure provides oral dosage forms comprising a tablet core and a coating layer, the tablet core comprising (i) a drug layer comprising 100 mg apremilast, 100 mg hydroxypropyl methylcellulose acetate succinate (HPMCAS), 301.4 mg polyethylene oxide, 26.7 mg sodium chloride, 2.6 mg magnesium stearate, and 2.7 mg colloidal silica, wherein the apremilast and HPMCAS are in a solid dispersion; and (ii) an expandable layer comprising 173.1 mg polyethylene oxide, 68.8 mg microcrystalline cellulose, 22.9 mg sodium chloride, 0.5 mg iron oxide, and 1.3 mg magnesium stearate; the coating layer is disposed on the tablet core and comprises cellulose acetate and polyethylene glycol; wherein the surface of the oral dosage form comprises at least one drug release pore.
[0070] In some embodiments, this disclosure provides oral dosage forms comprising a tablet core and a coating layer, the tablet core comprising (i) a drug layer comprising 100 mg apremilast, 100 mg hydroxypropyl methylcellulose acetate succinate (HPMCAS), 274.6 mg polyethylene oxide, 53.3 mg sodium chloride, 2.6 mg magnesium stearate, and 2.7 mg colloidal silica, wherein the apremilast and HPMCAS are in a solid dispersion; and (ii) an expandable layer comprising 173.1 mg polyethylene oxide, 68.8 mg microcrystalline cellulose, 22.9 mg sodium chloride, 0.5 mg iron oxide, and 1.3 mg magnesium stearate; the coating layer is disposed on the tablet core and comprises cellulose acetate and polyethylene glycol; wherein the surface of the oral dosage form comprises at least one drug release pore.
[0071] In some embodiments, this disclosure provides an oral dosage form comprising a) a tablet core comprising (i) a drug layer comprising 60 mg apremilast, 60 mg hydroxypropyl methylcellulose acetate succinate (HPMCAS), 48 mg mannitol, 307.2 mg polyethylene oxide, 2.4 mg magnesium stearate, and 2.4 mg colloidal silica, wherein the apremilast and HPMCAS are in a solid dispersion; and (ii) an expandable layer comprising 155.8 mg polyethylene oxide, 61.9 mg microcrystalline cellulose, 20.6 mg sodium chloride, 0.5 mg iron oxide, and 1.2 mg magnesium stearate; and b) a coating layer comprising 37.4 mg CA and 9.4 mg PEG, wherein the oral dosage form comprises at least one drug release pore as described herein.
[0072] In some embodiments, this disclosure provides an oral dosage form comprising a) a tablet core comprising (i) a drug layer comprising 60 mg apremilast, 60 mg hydroxypropyl methylcellulose acetate succinate (HPMCAS), 48 mg mannitol, 307.2 mg polyethylene oxide, 2.4 mg magnesium stearate, and 2.4 mg colloidal silica, wherein the apremilast and HPMCAS are in a solid dispersion; (ii) an expandable layer comprising 155.8 mg polyethylene oxide, 61.9 mg microcrystalline cellulose, 20.6 mg sodium chloride, 0.5 mg iron oxide, and 1.2 mg magnesium stearate; and b) a coating layer comprising 72.0 mg CA and 18.0 mg PEG, wherein the oral dosage form comprises at least one drug release pore as described herein.
[0073] In some embodiments, this disclosure provides an oral dosage form comprising a) a tablet core comprising (i) a drug layer comprising 65 mg apremilast, 65 mg hydroxypropyl methylcellulose acetate succinate (HPMCAS), 52 mg mannitol, 332.8 mg polyethylene oxide, 2.6 mg magnesium stearate, and 2.6 mg colloidal silica, wherein the apremilast and HPMCAS are in a solid dispersion; (ii) an expandable layer comprising 168.7 mg polyethylene oxide, 67.1 mg microcrystalline cellulose, 22.4 mg sodium chloride, 0.5 mg iron oxide, and 1.3 mg magnesium stearate; and b) a coating layer comprising 37.4 mg CA and 9.4 mg PEG, wherein the oral dosage form comprises at least one drug release pore as described herein.
[0074] In some embodiments, this disclosure provides an oral dosage form comprising a) a tablet core comprising (i) a drug layer comprising 65 mg apremilast, 65 mg hydroxypropyl methylcellulose acetate succinate (HPMCAS), 52 mg mannitol, 332.8 mg polyethylene oxide, 2.6 mg magnesium stearate, and 2.6 mg colloidal silica, wherein the apremilast and HPMCAS are in a solid dispersion; (ii) an expandable layer comprising 168.7 mg polyethylene oxide, 67.1 mg microcrystalline cellulose, 22.4 mg sodium chloride, 0.5 mg iron oxide, and 1.3 mg magnesium stearate; and b) a coating layer comprising 74.9 mg CA and 18.7 mg PEG, wherein the oral dosage form comprises at least one drug release pore as described herein.
[0075] In some embodiments, this disclosure provides an oral dosage form comprising a) a tablet core comprising (i) a drug layer comprising 70 mg apremilast, 70 mg hydroxypropyl methylcellulose acetate succinate (HPMCAS), 56 mg mannitol, 358.4 mg polyethylene oxide, 2.8 mg magnesium stearate, and 2.8 mg colloidal silica, wherein the apremilast and HPMCAS are in a solid dispersion; (ii) an expandable layer comprising 181.7 mg polyethylene oxide, 72.3 mg microcrystalline cellulose, 24.1 mg sodium chloride, 0.5 mg iron oxide, and 1.4 mg magnesium stearate; and b) a coating layer comprising 40.3 mg CA and 10.1 mg PEG, wherein the oral dosage form comprises at least one drug release pore as described herein.
[0076] In some embodiments, this disclosure provides an oral dosage form comprising a) a tablet core comprising (i) a drug layer comprising 75 mg apremilast, 75 mg hydroxypropyl methylcellulose acetate succinate (HPMCAS), 22.1 mg mannitol, 314.8 mg polyethylene oxide, 2.4 mg magnesium stearate, and 2.5 mg colloidal silica, wherein the apremilast and HPMCAs are in a solid dispersion; (ii) an expandable layer comprising 159.6 mg polyethylene oxide, 63.4 mg microcrystalline cellulose, 21.1 mg sodium chloride, 0.5 mg iron oxide, and 1.2 mg magnesium stearate; b) a base coat comprising 18.4 mg HPMC; and c) a coating layer comprising 36.3 mg CA and 9.1 mg PEG, wherein the oral dosage form comprises at least one drug release pore as described herein.
[0077] In some embodiments, this disclosure provides an oral dosage form comprising a) a tablet core comprising (i) a drug layer comprising 75 mg apremilast, 75 mg hydroxypropyl methylcellulose acetate succinate (HPMCAS), 22.1 mg mannitol, 314.8 mg polyethylene oxide, 2.4 mg magnesium stearate, and 2.5 mg colloidal silica, wherein the apremilast and HPMCAs are in a solid dispersion; (ii) an expandable layer comprising 159.6 mg polyethylene oxide, 63.4 mg microcrystalline cellulose, 21.1 mg sodium chloride, 0.5 mg iron oxide, and 1.2 mg magnesium stearate; b) a base coat comprising 18.4 mg HPMC; and c) a coating layer comprising 49.6 mg CA and 12.4 mg PEG, wherein the oral dosage form comprises at least one drug release pore as described herein.
[0078] In some embodiments, this disclosure provides an oral dosage form comprising a) a tablet core comprising (i) a drug layer comprising 75 mg apremilast, 75 mg hydroxypropyl methylcellulose acetate succinate (HPMCAS), 22.1 mg mannitol, 314.8 mg polyethylene oxide, 2.4 mg magnesium stearate, and 2.5 mg colloidal silica, wherein the apremilast and HPMCAS are in a solid dispersion; (ii) an expandable layer comprising 159.6 mg polyethylene oxide, 63.4 mg microcrystalline cellulose, 21.1 mg sodium chloride, 0.5 mg iron oxide, and 1.2 mg magnesium stearate; b) a coating layer comprising 41.3 mg CA and 10.3 mg PEG, wherein the coating layer further comprises 27.6 mg colorant, wherein the oral dosage form comprises at least one drug release pore as described herein.
[0079] In some embodiments, this disclosure provides an oral dosage form comprising a) a tablet core comprising (i) a drug layer comprising 75 mg apremilast, 75 mg hydroxypropyl methylcellulose acetate succinate (HPMCAS), 22.1 mg mannitol, 314.8 mg polyethylene oxide, 2.4 mg magnesium stearate, and 2.5 mg colloidal silica, wherein the apremilast and HPMCAS are in a solid dispersion; (ii) an expandable layer comprising 159.6 mg polyethylene oxide, 63.4 mg microcrystalline cellulose, 21.1 mg sodium chloride, 0.5 mg iron oxide, and 1.2 mg magnesium stearate; and b) a coating layer comprising 41.3 mg CA and 10.3 mg PEG, wherein the coating layer further comprises 27.6 mg colorant, and the oral dosage form comprises at least one drug release pore as described herein.
[0080] In some embodiments, this disclosure provides an oral dosage form comprising a) a tablet core comprising (i) a drug layer comprising 55 mg apremilast, 55 mg hydroxypropyl methylcellulose acetate succinate (HPMCAS), 16.2 mg mannitol, 230.9 mg polyethylene oxide, 1.7 mg magnesium stearate, and 1.8 mg colloidal silica, wherein the apremilast and HPMCAS are in a solid dispersion; (ii) an expandable layer comprising 117 mg polyethylene oxide, 46.5 mg microcrystalline cellulose, 15.5 mg sodium chloride, 0.4 mg iron oxide, and 0.9 mg magnesium stearate; and b) a coating layer comprising 30.3 mg CA and 7.6 mg PEG, wherein the coating layer further comprises 20.2 mg colorant, and the oral dosage form comprises at least one drug release pore as described herein.
[0081] In some embodiments, this disclosure provides an oral dosage form comprising a) a tablet core comprising (i) a drug layer comprising 27.5 mg apremilast, 27.5 mg hydroxypropyl methylcellulose succinate (HPMCAS), 8.1 mg mannitol, 115.6 mg polyethylene oxide, 1 mg magnesium stearate, and 0.9 mg colloidal silica, wherein the apremilast and HPMCAS are in a solid dispersion; (ii) an expandable layer comprising 58.6 mg polyethylene oxide, 23.3 mg microcrystalline cellulose, 7.8 mg sodium chloride, 0.2 mg iron oxide, and 0.5 mg magnesium stearate; and b) a coating layer comprising 15.2 mg CA and 3.8 mg PEG, wherein the coating layer further comprises 10.1 mg colorant, and the oral dosage form comprises at least one drug release pore as described herein.
[0082] In some embodiments, this disclosure provides an oral dosage form comprising a) a tablet core comprising (i) a drug layer comprising 100 mg apremilast, 100 mg hydroxypropyl methylcellulose succinate (HPMCAS), 26.7 mg mannitol, 150.7 mg polyethylene oxide having a MW of 300,000 Da, 150.7 mg polyethylene oxide having a MW of 200,000 Da, 2.6 mg magnesium stearate, and 2.7 mg colloidal silica, wherein the apremilast and HPMCAS are in a solid dispersion; (ii) an expandable layer comprising 173.1 mg polyethylene oxide, 68.8 mg microcrystalline cellulose, 22.9 mg sodium chloride, 0.5 mg iron oxide, and 1.3 mg magnesium stearate; and b) a coating layer as described herein, wherein the oral dosage form comprises at least one drug release pore as described herein.
[0083] In some embodiments, this disclosure provides an oral dosage form comprising a) a tablet core comprising (i) a drug layer comprising 100 mg apremilast, 100 mg hydroxypropyl methylcellulose succinate (HPMCAS), 53.3 mg sodium chloride, 274.6 mg polyethylene oxide having 300,000 Da MW, 2.6 mg magnesium stearate, and 2.7 mg colloidal silica, wherein the apremilast and HPMCAS are in a solid dispersion; (ii) an expandable layer comprising 173.1 mg polyethylene oxide, 68.8 mg microcrystalline cellulose, 22.9 mg sodium chloride, 0.5 mg iron oxide, and 1.3 mg magnesium stearate; and b) a coating layer as described herein, wherein the oral dosage form comprises at least one drug release pore as described herein.
[0084] In some embodiments, this disclosure provides an oral dosage form comprising a) a tablet core comprising (i) a drug layer comprising 75 mg apremilast, 75 mg hydroxypropyl methylcellulose succinate (HPMCAS), 40 mg sodium chloride, 206 mg polyethylene oxide having a MW of 300,000 Da, 2 mg magnesium stearate, and 2 mg colloidal silica, wherein the apremilast and HPMCAS are in a solid dispersion; (ii) an expandable layer comprising 129.8 mg polyethylene oxide, 51.6 mg microcrystalline cellulose, 17.2 mg sodium chloride, 0.4 mg iron oxide, and 1 mg magnesium stearate; and b) a coating layer as described herein, wherein the oral dosage form comprises at least one drug release pore as described herein.
[0085] In some embodiments, this disclosure provides an oral dosage form comprising a) a tablet core comprising (i) a drug layer comprising 75 mg apremilast, 75 mg hydroxypropyl methylcellulose acetate succinate (HPMCAS), 40 mg sodium chloride, 274.6 mg polyethylene oxide having a MW of 300,000 Da, 2 mg magnesium stearate, 50 mg mannitol, and 2 mg colloidal silica, wherein the apremilast and HPMCAS are in a solid dispersion; (ii) an expandable layer comprising 173.1 mg polyethylene oxide, 68.8 mg microcrystalline cellulose, 22.9 mg sodium chloride, 0.5 mg iron oxide, and 1.3 mg magnesium stearate; and b) a coating layer as described herein, wherein the oral dosage form comprises at least one drug release pore as described herein.
[0086] In some embodiments, this disclosure provides an oral dosage form comprising a) a tablet core comprising (i) a drug layer comprising 75 mg apremilast, 75 mg hydroxypropyl methylcellulose acetate succinate (HPMCAS), 40 mg sodium chloride, 274.6 mg polyethylene oxide having a MW of 300,000 Da, 2 mg magnesium stearate, 25 mg mannitol (IG), 25 mg mannitol (EG), and 2 mg colloidal silica, wherein the apremilast and HPMCAS are in a solid dispersion; (ii) an expandable layer comprising 173.1 mg polyethylene oxide, 68.8 mg microcrystalline cellulose, 22.9 mg sodium chloride, 0.5 mg iron oxide, and 1.3 mg magnesium stearate; and b) a coating layer as described herein, wherein the oral dosage form comprises at least one drug release pore as described herein. Treatment Methods
[0087] This disclosure provides a method for treating a patient suffering from a disease or disorder that is alleviated by inhibiting PDE4, the method comprising administering the oral dosage form disclosed herein to the patient under eating conditions.
[0088] A subject in a feeding state refers to a subject who has already eaten or consumed a meal. In some embodiments, the preparation disclosed herein is administered to a subject in a feeding state 5 minutes, 10 minutes, 15 minutes, 20 minutes, 30 minutes, 40 minutes, 50 minutes, 1 hour, or 2 hours after a meal. In some cases, the preparation disclosed herein is administered to a subject in a feeding state 30 minutes after a meal. In all cases, the preparation disclosed herein is administered to a subject in a feeding state 1 hour after a meal. In some embodiments, the preparation disclosed herein is administered to the subject along with food.
[0089] In some embodiments, the disease or disorder is asthma, arthritis, psoriasis, inflammation, chronic or acute obstructive pulmonary disease, chronic or acute pneumonia, cutaneous lupus erythematosus, inflammatory bowel disease, Crohn's disease, Behcet's disease, or colitis. In some embodiments, the disease or disorder is arthritis. In some embodiments, the arthritis is psoriatic arthritis. In some embodiments, the disease or disorder is psoriasis. In some embodiments, the disease or disorder is colitis. In some embodiments, the colitis is ulcerative colitis. In some embodiments, the disease or disorder is Behcet's disease.
[0090] In some embodiments, the disclosed oral dosage form is administered after initial titration with a conventional twice-daily apremilast formulation.
[0091] In some embodiments, the disclosed method includes the following initial titration schedule: (i) 10 mg in the morning on the first day of administration; (ii) 10 mg in the morning and 10 mg in the afternoon on the second day of administration; (iii) 10 mg in the morning and 20 mg in the afternoon on the third day of administration; (iv) 20 mg in the morning and 20 mg in the afternoon on the fourth day of administration; (v) 20 mg in the morning and 30 mg in the afternoon on the fifth day of administration; and (vi) 30 mg in the morning and 30 mg in the afternoon on days 6–14 of administration; and the disclosed oral dosage form, once daily, every day following administration. In some embodiments, the oral dosage form administered on day 15 and thereafter comprises 27.5 mg apremilast, 55 mg apremilast, or 75 mg apremilast.
[0092] In some embodiments, the disclosed method includes the following initial titration schedule: (i) 10 mg in the morning on the first day of administration; (ii) 10 mg in the morning and 10 mg in the afternoon on the second day of administration; (iii) 10 mg in the morning and 20 mg in the afternoon on the third day of administration; (iv) 20 mg in the morning and 20 mg in the afternoon on the fourth day of administration; (v) 20 mg in the morning and 30 mg in the afternoon on the fifth day of administration; and (vi) 30 mg in the morning and 30 mg in the afternoon on days 6-14 of administration; and the disclosed oral dosage form with 75 mg apremilast, once daily, on day 15 and every morning thereafter.
[0093] In some embodiments, the disclosed method includes the following initial titration schedule: (i) 10 mg in the morning on the first day of administration; (ii) 10 mg in the morning and 10 mg in the afternoon on the second day of administration; (iii) 10 mg in the morning and 20 mg in the afternoon on the third day of administration; (iv) 20 mg in the morning and 20 mg in the afternoon on the fourth day of administration; (v) 20 mg in the morning and 30 mg in the afternoon on the fifth day of administration; and (vi) an oral dosage form of 75 mg apremilast as disclosed herein, once daily, on the morning of the sixth day and thereafter.
[0094] In some embodiments, the disclosed method includes the following initial titration schedule: (i) 10 mg in the morning of the first day of administration; (ii) 10 mg in the morning and 10 mg in the afternoon of the second day of administration; (iii) 10 mg in the morning and 20 mg in the afternoon of the third day of administration; and (iv) an oral dosage form of 55 mg apremilast as disclosed herein, once daily, on the morning of the fourth day and thereafter.
[0095] In some embodiments, the disclosed method includes the following initial titration schedule: (i) 10 mg in the morning on the first day of administration; (ii) 10 mg in the morning and 10 mg in the afternoon on the second day of administration; (iii) 10 mg in the morning and 20 mg in the afternoon on the third day of administration; (iv) 20 mg in the morning and 20 mg in the afternoon on days 4 through 14 of administration; and (v) in the oral dosage form of 55 mg apremilast as disclosed herein, once daily on the morning of day 15 and thereafter.
[0096] In some embodiments, the disclosed method includes the following initial titration schedule: (i) 10 mg in the morning on the first day of administration; (ii) 10 mg in the morning and 10 mg in the afternoon on the second day of administration; (iii) 10 mg in the morning and 20 mg in the afternoon on the third day of administration; and (iv) two oral dosage forms of 27.5 mg aprestin (total 55 mg aprestin) as disclosed herein, once daily, on the morning of the fourth day and thereafter.
[0097] In some embodiments, the disclosed method includes the following initial titration schedule: (i) 10 mg in the morning on the first day of administration; (ii) 10 mg in the morning and 10 mg in the afternoon on the second day of administration; (iii) 10 mg in the morning and 20 mg in the afternoon on the third day of administration; (iv) 20 mg in the morning and 20 mg in the afternoon on days 4 through 14 of administration; and (v) two oral dosage forms of 27.5 mg aprestin (total 55 mg aprestin) as disclosed herein, once daily on the morning of day 15 and thereafter. 1. An oral dosage form comprising: a. a tablet core comprising (i) a drug layer comprising apremilast and hydroxypropyl methylcellulose acetate succinate (HPMCAS) in an amorphous solid dispersion; and (ii) an expandable layer comprising one or more expandable polymers; and b. a coating layer disposed on the tablet core, wherein the surface of the oral dosage form comprises at least one drug release pore. 2. The oral dosage form of embodiment 1, wherein the apremilast is present in an amount of 6-15 wt% of the tablet core. 3. The oral dosage form of embodiment 1 or 2, wherein the solid dispersion system is spray-dried. 4. The oral dosage form of any one of embodiments 1-3, wherein the HPMCAS is present in an amount of 6-15 wt% of the tablet core. 5. An oral dosage form as described in any one of Embodiments 1-4, wherein apremilast and HPMCAS are present in the tablet core in a weight ratio of 45:55 to 55:45. 6. An oral dosage form as described in Embodiment 5, wherein apremilast and HPMCAS are present in a weight ratio of 48:52 to 52:48. 7. An oral dosage form as described in Embodiment 5, wherein apremilast and HPMCAS are present in a weight ratio of 50:50. 8. An oral dosage form as described in any one of Embodiments 1-7, wherein the drug layer further comprises one or more of a water-soluble polymer, a diluent, a penetrant, and a lubricant. 9. An oral dosage form as described in Embodiment 8, wherein the water-soluble polymer is present in an amount of 30-55 wt% of the tablet core. 10. An oral dosage form as described in Embodiment 8 or 9, wherein the water-soluble polymer comprises polyethylene oxide. 11. An oral dosage form as described in Embodiment 10, wherein the polyethylene oxide has an average molecular weight of 200,000-600,000 Da. 12. An oral dosage form as described in Embodiment 11, wherein the drug layer comprises polyethylene oxide having an average molecular weight of 200,000 Da. 13. An oral dosage form as described in Embodiment 11, wherein the drug layer comprises polyethylene oxide having an average molecular weight of 300,000 Da.14. An oral dosage form as described in Embodiment 11, wherein the drug layer comprises polyethylene oxide having an average molecular weight of 600,000 Da. 15. An oral dosage form as described in any one of Embodiments 8-14, wherein the water-soluble polymer and apremilast are present in the drug layer at a weight ratio of 2-6:1. 16. An oral dosage form as described in any one of Embodiments 8-15, wherein the diluent comprises mannitol. 17. An oral dosage form as described in any one of Embodiments 8-16, wherein the diluent is present in an amount of 2-7 wt% of the tablet core. 18. An oral dosage form as described in any one of Embodiments 8-17, wherein the drug layer comprises an in-particle diluent and an out-of-particle diluent. 19. An oral dosage form as described in any one of Embodiments 8-18, wherein the penetrant is present in an amount of 3-8 wt% of the tablet core. 20. An oral dosage form as described in any one of embodiments 8-19, wherein the penetrant in the drug layer comprises sodium chloride. 21. An oral dosage form as described in any one of embodiments 8-20, wherein the lubricant comprises magnesium stearate. 22. An oral dosage form as described in any one of embodiments 8-21, wherein the lubricant in the drug layer is present in an amount of 0.05-0.5 wt% of the tablet core. 23. An oral dosage form as described in any one of embodiments 1-22, wherein the drug layer further comprises an external lubricant, an external lubricant, or both. 24. An oral dosage form as described in embodiment 23, wherein the external lubricant comprises silicon dioxide. 25. An oral dosage form as described in embodiment 23 or 24, wherein the external lubricant comprises magnesium stearate. 26. An oral dosage form as described in any one of embodiments 1-25, wherein the drug layer and the expandable layer are present in the tablet core in a weight ratio of 2:1. 27. An oral dosage form as described in any one of Embodiments 1-26, wherein the expandable polymer comprises polyethylene oxide. 28. An oral dosage form as described in Embodiment 27, wherein the polyethylene oxide has an average molecular weight of 5,000,000 Da. 29. An oral dosage form as described in any one of Embodiments 1-28, wherein the expandable layer further comprises one or more of a penetrant, a diluent, a lubricant, and a colorant. 30. An oral dosage form as described in Embodiment 29, wherein the penetrant of the expandable layer comprises sodium chloride. 31. An oral dosage form as described in Embodiment 29 or 30, wherein the penetrant in the expandable layer is present in an amount of 2.5-3.5 wt% of the tablet core. 32. An oral dosage form as described in any one of Embodiments 29-31, wherein the diluent of the expandable layer comprises microcrystalline cellulose. 33. An oral dosage form as described in any one of embodiments 29-32, wherein the diluent in the expandable layer is present in an amount of 7-10 wt% of the tablet core.34. An oral dosage form as described in any one of embodiments 29-33, wherein the lubricant of the expandable layer comprises magnesium stearate. 35. An oral dosage form as described in any one of embodiments 29-34, wherein the lubricant of the expandable layer is present in an amount of 0.05-0.5 wt% of the tablet core. 36. An oral dosage form as described in any one of embodiments 29-35, wherein the colorant comprises iron oxide red. 37. An oral dosage form as described in any one of embodiments 29-36, wherein the colorant is present in an amount of 0.05-0.5 wt% of the tablet core. 38. An oral dosage form as described in any one of embodiments 1-37, wherein the coating comprises cellulose acetate and polyethylene glycol. 39. An oral dosage form as described in embodiment 38, wherein the cellulose acetate and polyethylene glycol are present in the coating in a weight ratio of 3.5-4.5:1. 40. An oral dosage form as described in any one of Embodiments 1-39, wherein the coating comprises 6.5-8.5 wt% of the total weight of the oral dosage form. 41. An oral dosage form as described in Embodiment 40, wherein the coating comprises 7.5 wt% of the total weight of the oral dosage form. 42. An oral dosage form as described in any one of Embodiments 1-41, further comprising a base coat layer between the wafer and the coating layer. 43. An oral dosage form as described in Embodiment 42, wherein the base coat layer comprises hydroxypropyl methylcellulose. 44. An oral dosage form as described in Embodiment 42 or 43, wherein the base coat layer is present in an amount of 2-4 wt% of the oral dosage form. 45. An oral dosage form as described in Embodiment 44, wherein the base coat layer is present in an amount of 2.3 wt% of the oral dosage form. 46. An oral dosage form as described in Embodiment 44, wherein the base coat layer is present in an amount of 3.4 wt% of the oral dosage form. 47. An oral dosage form as described in any one of Embodiments 1-46, wherein the drug layer comprises an inner portion and an outer portion. 48. An oral dosage form as described in Embodiment 47, wherein the outer portion comprises a lubricant and a slip agent. 49. An oral dosage form as described in Embodiment 48, wherein the outer portion further comprises a diluent. 50. An oral dosage form as described in Embodiment 49, wherein the lubricant comprises magnesium stearate, the slip agent comprises silicon dioxide, and the diluent comprises mannitol. 51. An oral dosage form as described in any one of Embodiments 47-50, wherein the inner portion comprises aprestil, HPMCAS, polyethylene oxide, and mannitol, and an inner lubricant. 52. An oral dosage form as described in Embodiment 51, wherein the inner lubricant comprises magnesium stearate. 53. An oral dosage form as described in any one of Embodiments 49-52, wherein the mannitol is present in both the inner and outer portions.54. An oral dosage form as described in Embodiment 53, wherein the oral dosage form comprises 55%-57% of the total mannitol present in the inner portion of the particle and 43%-45% of the total mannitol present in the outer portion of the particle. 55. An oral dosage form as described in any one of Embodiments 47-54, wherein the expandable layer further comprises a lubricant. 56. An oral dosage form as described in Embodiment 55, wherein the lubricant of the expandable layer comprises magnesium stearate. 57. An oral dosage form as described in any one of Embodiments 47-56, wherein the inner portion of the drug layer particle comprises sodium chloride. 58. An oral dosage form as described in any one of Embodiments 47-57, wherein the oral dosage form further comprises a colored coating layer in an amount of 3-5 wt% of the oral dosage form. 59. An oral dosage form as described in Embodiment 58, wherein the colored coating layer is present in an amount of 3.4 wt% of the oral dosage form. 60. An oral dosage form comprising: a. a tablet core comprising (i) a drug layer comprising 8-11 wt% aprestinum, 8-11 wt% hydroxypropyl methylcellulose acetate succinate (HPMCAS) based on the total weight of the tablet core, 2-7 wt% mannitol based on the total weight of the tablet core, 40-45 wt% polyethylene oxide with a molecular weight of 200,000 Da based on the total weight of the tablet core, 0.1-0.5 wt% magnesium stearate based on the total weight of the tablet core, and 0.1-0.5 wt% colloidal silica based on the total weight of the tablet core, wherein the aprestinum and HPMCAs are in a solid dispersion; (ii) an expandable layer comprising 18-25 wt% polyethylene oxide with a molecular weight of 5,000,000 Da based on the total weight of the tablet core, 7-10 wt% mannitol based on the total weight of the tablet core, 8-11 wt% hydroxypropyl methylcellulose acetate succinate (HPMCAS) based on the total weight of the tablet core, 2-7 wt% mannitol based on the total weight of the tablet core, 40-45 wt% polyethylene oxide with a molecular weight of 200,000 Da, 7-10 wt% magnesium stearate based on the total weight of the tablet core, and 0.1-0.5 wt% colloidal silica based on the total weight of the tablet core. a. wt% microcrystalline cellulose, 1.5-3.5 wt% sodium chloride based on the total weight of the tablet core, 0.01-0.2 wt% iron oxide based on the total weight of the tablet core, and 0.05-0.3 wt% magnesium stearate based on the total weight of the tablet core; and b. a coating layer disposed on the tablet core and comprising cellulose acetate and polyethylene glycol; wherein the oral dosage form surface comprises at least one drug release pore.61. An oral dosage form as described in Embodiment 60, comprising: a. a tablet core comprising (i) a drug layer comprising 75 mg apremilast, 75 mg hydroxypropyl methylcellulose acetate succinate (HPMCAS), 22.1 mg mannitol, 314.8 mg polyethylene oxide with a molecular weight of 200,000 Da, 2.4 mg magnesium stearate, and 2.5 mg colloidal silicon dioxide, wherein the apremilast and HPMCAS are in a solid dispersion; (ii) an expandable layer comprising 159.6 mg polyethylene oxide with a molecular weight of 5,000,000 Da, 63.4 mg microcrystalline cellulose, 21.1 mg sodium chloride, 0.5 mg iron oxide, and 1.2 mg magnesium stearate; and b. a coating layer disposed on the tablet core and comprising cellulose acetate and polyethylene glycol; wherein the oral dosage form surface comprises at least one drug release pore. 62. An oral dosage form as described in embodiment 60, comprising: a. a tablet core comprising (i) a drug layer comprising 55 mg apremilast, 55 mg hydroxypropyl methylcellulose acetate succinate (HPMCAS), 16.2 mg mannitol, 230.9 mg polyethylene oxide with a molecular weight of 200,000 Da, 1.7 mg magnesium stearate, and 1.8 mg colloidal silica, wherein the apremilast and HPMCAS are in a solid dispersion; (ii) an expandable layer comprising 117 mg polyethylene oxide with a molecular weight of 5,000,000 Da, 46.5 mg microcrystalline cellulose, 15.5 mg sodium chloride, 0.4 mg iron oxide, and 0.9 mg magnesium stearate; and b. a coating layer disposed on the tablet core and comprising cellulose acetate and polyethylene glycol; wherein the oral dosage form surface comprises at least one drug release pore. 63. An oral dosage form as described in Embodiment 60, comprising: a. a tablet core comprising (i) a drug layer comprising 27.5 mg apremilast, 27.5 mg hydroxypropyl methylcellulose acetate succinate (HPMCAS), 8.1 mg mannitol, 115.6 mg polyethylene oxide with a molecular weight of 200,000 Da, 1.0 mg magnesium stearate, and 0.9 mg colloidal silicon dioxide, wherein the apremilast and HPMCAS are in a solid dispersion; (ii) an expandable layer comprising 58.6 mg polyethylene oxide with a molecular weight of 5,000,000 Da, 23.3 mg microcrystalline cellulose, 7.8 mg sodium chloride, 0.2 mg iron oxide, and 0.5 mg magnesium stearate; and b. a coating layer disposed on the tablet core and comprising cellulose acetate and polyethylene glycol; wherein the surface of the oral dosage form comprises at least one drug release pore.64. An oral dosage form comprising: a. a tablet core comprising (i) a drug layer comprising 9-15 wt% aprestinum, 10-15 wt% hydroxypropyl methylcellulose succinate (HPMCAS) based on the total weight of the tablet core, 0-27 wt% mannitol based on the total weight of the tablet core, 30-40 wt% polyethylene oxide or a mixture thereof with a molecular weight of 200,000-300,000 Da based on the total weight of the tablet core, 2-8 wt% sodium chloride based on the total weight of the tablet core, 0.1-0.5 wt% magnesium stearate based on the total weight of the tablet core, and 0.1-0.5 wt% colloidal silicon dioxide based on the total weight of the tablet core, wherein the aprestinum and HPMCAs are in a solid dispersion; and (ii) an expandable layer comprising 15-25 wt% of a molecular weight of 5,000,000 Da based on the total weight of the tablet core. A. Polyethylene oxide, 5-10.0 wt% microcrystalline cellulose based on the total weight of the tablet core, 2-4 wt% sodium chloride based on the total weight of the tablet core, 0.01-0.1 wt% iron oxide based on the total weight of the tablet core, and 0.05-0.3 wt% magnesium stearate based on the total weight of the tablet core; and b. a coating layer disposed on the tablet core and comprising cellulose acetate and polyethylene glycol; wherein the oral dosage form surface comprises at least one drug release pore. 65. An oral dosage form as described in Embodiment 64, comprising: a. a tablet core comprising (i) a drug layer comprising 100 mg apremilast, 100 mg hydroxypropyl methylcellulose acetate succinate (HPMCAS), 301.4 mg of polyethylene oxide or a mixture thereof with a molecular weight of 200,000-300,000 Da, 26.7 mg sodium chloride, 2.6 mg magnesium stearate, and 2.7 mg colloidal silicon dioxide, wherein the apremilast and HPMCAS are in a solid dispersion; (ii) an expandable layer comprising 173.1 mg of polyethylene oxide with a molecular weight of 5,000,000 Da, 68.8 mg microcrystalline cellulose, 22.9 mg sodium chloride, 0.5 mg iron oxide, and 1.3 mg magnesium stearate; and b. A coating layer is disposed on the tablet core and comprises cellulose acetate and polyethylene glycol; wherein the surface of the oral dosage form includes at least one drug release pore.66. An oral dosage form as described in Embodiment 64, comprising: a. a tablet core comprising (i) a drug layer comprising 100 mg apremilast, 100 mg hydroxypropyl methylcellulose acetate succinate (HPMCAS), 274.6 mg polyethylene oxide with a molecular weight of 300,000 Da, 53.3 mg sodium chloride, 2.6 mg magnesium stearate, and 2.7 mg colloidal silicon dioxide, wherein the apremilast and HPMCAS are in a solid dispersion; (ii) an expandable layer comprising 173.1 mg polyethylene oxide with a molecular weight of 5,000,000 Da, 68.8 mg microcrystalline cellulose, 22.9 mg sodium chloride, 0.5 mg iron oxide, and 1.3 mg magnesium stearate; and b. a coating layer disposed on the tablet core and comprising cellulose acetate and polyethylene glycol; wherein the surface of the oral dosage form comprises at least one drug release pore. 67. An oral dosage form as described in Embodiment 64, comprising: a. a tablet core comprising (i) a drug layer comprising 75 mg apremilast, 75 mg hydroxypropyl methylcellulose acetate succinate (HPMCAS), 226.0 mg of polyethylene oxide or a mixture thereof with a molecular weight of 200,000-300,000 Da, 20.0 mg sodium chloride, 2.0 mg magnesium stearate, and 2.0 mg colloidal silicon dioxide, wherein the apremilast and HPMCAS are in a solid dispersion; (ii) an expandable layer comprising 129.8 mg of polyethylene oxide with a molecular weight of 5,000,000 Da, 51.6 mg microcrystalline cellulose, 17.2 mg sodium chloride, 0.4 mg iron oxide, and 1.0 mg magnesium stearate; and b. A coating layer is disposed on the tablet core and comprises cellulose acetate and polyethylene glycol; wherein the surface of the oral dosage form includes at least one drug release pore. 68. An oral dosage form as described in Embodiment 64, comprising: a. a tablet core comprising (i) a drug layer comprising 75 mg apremilast, 75 mg hydroxypropyl methylcellulose acetate succinate (HPMCAS), 206.0 mg polyethylene oxide with a molecular weight of 300,000 Da, 40.0 mg sodium chloride, 2.0 mg magnesium stearate, and 2.0 mg colloidal silicon dioxide, wherein the apremilast and HPMCAS are in a solid dispersion; (ii) an expandable layer comprising 129.8 mg polyethylene oxide with a molecular weight of 5,000,000 Da, 51.6 mg microcrystalline cellulose, 17.2 mg sodium chloride, 0.4 mg iron oxide, and 1.0 mg magnesium stearate; and b. a coating layer disposed on the tablet core and comprising cellulose acetate and polyethylene glycol; wherein the oral dosage form surface comprises at least one drug release pore.69. An oral dosage form as described in Embodiment 64, comprising: a. a tablet core comprising (i) a drug layer comprising 55 mg apremilast, 55 mg hydroxypropyl methylcellulose acetate succinate (HPMCAS), 165.7 mg of polyethylene oxide or a mixture thereof with a molecular weight of 200,000-300,000 Da, 14.7 mg sodium chloride, 1.4 mg magnesium stearate, and 1.5 mg colloidal silicon dioxide, wherein the apremilast and HPMCAS are in a solid dispersion; (ii) an expandable layer comprising 95.2 mg of polyethylene oxide with a molecular weight of 5,000,000 Da, 37.8 mg microcrystalline cellulose, 12.6 mg sodium chloride, 0.3 mg iron oxide, and 0.7 mg magnesium stearate; and b. A coating layer is disposed on the tablet core and comprises cellulose acetate and polyethylene glycol; wherein the surface of the oral dosage form includes at least one drug release pore. 70. An oral dosage form as described in Embodiment 64, comprising: a. a tablet core comprising (i) a drug layer comprising 55 mg aprestinum, 55 mg hydroxypropyl methylcellulose acetate succinate (HPMCAS), 151.1 mg polyethylene oxide with a molecular weight of 300,000 Da, 29.3 mg sodium chloride, 1.4 mg magnesium stearate, and 1.5 mg colloidal silica, wherein the aprestinum and HPMCAS are in a solid dispersion; (ii) an expandable layer comprising 95.2 mg polyethylene oxide with a molecular weight of 5,000,000 Da, 37.8 mg microcrystalline cellulose, 12.6 mg sodium chloride, 0.3 mg iron oxide, and 0.7 mg magnesium stearate; and b. a coating layer disposed on the tablet core and comprising cellulose acetate and polyethylene glycol; wherein the oral dosage form surface comprises at least one drug release pore.71. An oral dosage form as described in Embodiment 64, comprising: a. a tablet core comprising (i) a drug layer comprising 27.5 mg apremilast, 27.5 mg hydroxypropyl methylcellulose acetate succinate (HPMCAS), 82.9 mg polyethylene oxide or a mixture thereof with a molecular weight of 200,000-300,000 Da, 7.3 mg sodium chloride, 0.8 mg magnesium stearate, and 0.7 mg colloidal silicon dioxide, wherein the apremilast and HPMCAS are in a solid dispersion; (ii) an expandable layer comprising 47.6 mg polyethylene oxide with a molecular weight of 5,000,000 Da, 18.9 mg microcrystalline cellulose, 6.3 mg sodium chloride, 0.1 mg iron oxide, and 0.4 mg magnesium stearate; and b. A coating layer is disposed on the tablet core and comprises cellulose acetate and polyethylene glycol; wherein the surface of the oral dosage form includes at least one drug release pore. 72. An oral dosage form as described in Embodiment 64, comprising: a. a tablet core comprising (i) a drug layer comprising 27.5 mg apremilast, 27.5 mg hydroxypropyl methylcellulose acetate succinate (HPMCAS), 75.5 mg polyethylene oxide with a molecular weight of 300,000 Da, 14.7 mg sodium chloride, 0.4 mg magnesium stearate, and 0.7 mg colloidal silicon dioxide, wherein the apremilast and HPMCAS are in a solid dispersion; (ii) an expandable layer comprising 47.6 mg polyethylene oxide with a molecular weight of 5,000,000 Da, 18.9 mg microcrystalline cellulose, 6.3 mg sodium chloride, 0.1 mg iron oxide, and 0.4 mg magnesium stearate; and b. a coating layer disposed on the tablet core and comprising cellulose acetate and polyethylene glycol; wherein the surface of the oral dosage form comprises at least one drug release pore. 73. A method for treating a patient suffering from a disease or disorder alleviated by inhibiting PDE4, the method comprising administering to the patient once daily, under eating conditions, an oral dosage form as described in any one of embodiments 1-72. 74. The method as described in embodiment 73, wherein the disease or disorder is psoriasis, psoriatic arthritis, or Behçet's disease. Example.
[0098] The following examples further illustrate the disclosed treatment methods, but should not be construed as limiting their scope in any way.
[0099] The following abbreviations are used in this example: SCT refers to Expandable Core Technology; TAB refers to Tablets; SDD refers to Amorphous Spray-Dried Dispersion; APR refers to Amorphous Aptamil; HPMCAS refers to Hydroxypropyl Methylcellulose Acetate Succinate; HPMC refers to Hydroxypropyl Methylcellulose; DL refers to Drug Layer; SL refers to Expandable Layer; CL refers to Coating Layer; PEO refers to Polyethylene Oxide; PEG refers to Polyethylene Glycol; Mg refers to Magnesium; IG refers to In-particle; EG refers to Out-of-particle; MCC refers to Microcrystalline Cellulose; NaCl refers to Sodium Chloride; MW refers to Molecular Weight; cSiO2 refers to Colloidal Silicon Dioxide; CA refers to Cellulose Acetate; RR refers to Release Rate; SRC refers to Standard Circular Die; SEM refers to Scanning Electron Microscopy; inWC refers to Water Column Inches; AUC0-∞ refers to the area under the plasma concentration-time curve calculated from time zero to infinity; AUC0-t refers to the area under the plasma concentration-time curve calculated from time zero to infinity. The area under the concentration-time curve calculated from the zero point of time to the last measurement point; CL / F refers to the apparent clearance of the drug from plasma after extravasation; Cmax refers to the observed maximum drug concentration; Ctrough refers to the plasma concentration observed at the end of the dosing interval; CI refers to the confidence interval; CV% refers to the coefficient of variation; t1 / 2 refers to the terminal elimination half-life; tlag refers to the delay between the dosing time and the onset of the absorption lag time; tmax refers to the time to reach Cmax; Vz / F refers to the terminal apparent volume of distribution; Frel1 refers to the relative bioavailability of each test formulation compared to the reference formulation; Frel2 refers to the relative bioavailability of each dose-normalized test formulation compared to the dose-normalized reference formulation IR tablets; and RA refers to the accumulation rate based on the area under the plasma concentration-time curve on day 1 and day 5 over a 24-hour period. Example 1
[0100] This example demonstrates the preparation of amorphous spray-dried solid dispersions containing 48 wt% and 52 wt% Apstec loadings in batches of 2 kg each using a PSD-1 scale spray dryer.
[0101] Solutions were prepared with 12% total solids in acetone at 48:52 APR: HPMCAS-LG and 52:48 APR: HPMCAS-LG (Tables 1 and 2). Solutions were sprayed in increasing order of drug loading, with a light cleaning performed between sprays (e.g., flushing the chamber and piping system with water and a cleaning agent (e.g., alkaline cleaner; CIP-100), and flushing the feed pump with acetone). Drying kinetics and thermodynamics were consistent with historical 50% Apsera SDD runs. A 48% drug loading SDD achieved an 82% wet yield, followed by a 67% wet yield with a 52% drug loading SDD. Wet yields were calculated based on the total net weight collected from the spray dryer (excluding start / stop quantities and pre-wetted SDD samples) and on a 2 kg feed solids basis. Average operating conditions and wet yields for the two SDD batches are listed in Table 3. [Table 1]. 48: 52 APR: HPMCAS-LG SDD In acetone, at 12 wt% solids, 48:52 APR: HPMCAS-LG Element mixture% SDD mg / g Apst 5.76 480.0 HPMCAS-LG 6.24 520.0 acetone 88.00 0.0 [Table 2]. 52: 48 APR: HPMCAS-LG SDD In acetone, 12 wt% solids, 52:48 APR: HPMCAS-LG Element mixture% SDD mg / g Apst 6.24 520.0 HPMCAS-LG 5.76 480.0 acetone 88.00 0.0 [Table 3]. Average operating conditions and wet recovery rates for 48% and 52% APR SDD SDD composition 48:52 APR: HPMCAS-LG 48:52 APR: HPMCAS-LG N2 flow rate (g / min) 1850 1854 Solution flow rate (g / min) 201 200 Nebulization pressure (psi) 496 517 Inlet temperature (°C) 106 106 Outlet temperature (°C) 41 41 Cyclone pressure differential (inWC) 11 11 Filter DP (inWC) 5 5 wet yield 82% 67%
[0102] Once all wet SDD samples were collected, bulk SDDs from both drug loadings were subjected to secondary drying using a convection disc dryer at 40°C and 15% relative humidity (RH). The 48% APR SDD was dried for 1100 minutes, and the 52% APR SDD for 505 minutes. Based on the total net weight collected from the disc dryer (including the dried SDD samples and the wet SDD samples assuming a 5% solvent loss) and calculated based on a 2 kg feed solids, the dry yields of the 48% and 52% drug loading SDDs were 78% and 64%, respectively.
[0103] The particle size distribution of dried SDDs for each drug loading was then characterized using laser diffraction with a Malvern Mastersizer 2000 (Malvern Panalytical, Malvern, UK). The average particle size data are shown in Table 4. Both drug loadings had the same particle size of 33 µm (D[4,3]), indicating that minor differences in composition did not affect the particle size. [Table 4]. Particle size data for 48% and 52% Apsera SDDs. sample average value D(v 0.1) µm D(v 0.5)µm D(v 0.9) µm D[3,2]µm D[4,3]µm span 48:52 APR: HPMCAS-LG dry SDD 8 30 63 13 33 1.9 52:48 APR: HPMCAS-LG dry SDD 7 29 64 13 33 2.0 *Values obtained using a dispersion pressure of 1 bar and a vibratory feed rate of 65%.
[0104] The characterization of SDD is summarized in Table 5, including residual acetone determined by gas chromatography (GC), crystallinity determined by powder X-ray diffraction (PXRD), thermal properties determined by modulated differential scanning calorimetry (mDSC), content and related substances determined by high performance liquid chromatography (HPLC), performance determined by microcentrifugation dissolution, and morphology determined by scanning electron microscopy (SEM). [Table 5]. Physical characterization of 48% and 52% Apstar SDD SDD composition 48:52 APR: HPMCAS-LG 52:48 APR: HPMCAS-LG Residual acetone before secondary drying 3.7 wt% 3.8 wt% Residual acetone after secondary drying 0.07 wt% 0.17 wt% Residual water after secondary drying (KF) 0.81 wt%, 6.0% RSD 0.72 wt%, 4.7% RSD Apparentity measured by SEM Smooth collapse And the uncollapsed sphere, without Crystal signs Smooth collapse And the uncollapsed sphere, without Crystal signs Crystallinity determined by PXRD Not detected Not detected Glass transition temperature measured by mDSC 79.7°C 80.5°C Content determined by HPLC (wt% APR) 47.1 wt% 50.8 wt% Related substances Not detected Not detected Microcentrifuge dissolution C maxSIF1200 = 504 µg / mL, AUC SIF = 43,180 min*µg / mL C maxSIF1200 = 479 µg / mL, AUC SIF = 40,780 min* µg / mL
[0105] As shown in Table 5, there was no significant difference in residual acetone content between 48% and 52% APR SDD after spray drying and before secondary drying. Due to the shorter drying time, the 52% APR SDD had slightly higher residual acetone content after secondary drying, but both batches were below the ICH limit of 5000 ppm. The 48% APR SDD was dried for 1100 minutes, and the 52% APR SDD was dried for 505 minutes. Similarly, there was no measurable difference in glass transition temperature.
[0106] SEM analysis showed that both 48% and 52% APR SDDs consisted of smooth collapsed and uncollapsed spheres, with no signs of crystallization. Compared to 48% APR SDDs, 52% APR SDDs appeared to have a greater number of uncollapsed spheres and a greater number of broken particles. SDD Stability Study - Wet SDD Retention Time Study
[0107] SDDs with drug loadings of 48% and 52% (by weight) were manufactured using a PSD-1 scale spray dryer as described herein. Each batch of wet SDDs was stored in LDPE bags within sealed stainless steel containers and at 27°C for up to 30 days. Samples were taken from each batch on days 10, 20, and 30 and characterized by SEM, mDSC, PXRD, content and related substances determined by HPLC, residual solvents, and non-precipitation dissolution (microcentrifuge dissolution test).
[0108] SEM analysis showed that both 48% and 52% APR SDD contained smooth collapsed and non-collapsed spheres, with no signs of fusion or crystallization. No changes in morphology or physical state were observed after 30 days of storage before secondary drying. PXRD analysis indicated that no crystallization occurred for either 48% or 52% APR SDD throughout the 30-day stability study. Furthermore, no morphological changes indicating crystallization were observed within the capabilities of the SEM analytical method. DSC thermal analysis plots showed no measurable difference in Tg between the stable samples and the dried SDD. No increase in impurities was observed in content and related substances during the 30-day stability retention period. Similarly, microcentrifuge dissolution results showed no difference in performance over 30 days. Example 2
[0109] This embodiment illustrates a tablet dosage form according to an embodiment of the present disclosure.
[0110] Fourteen apremilast SCT dosage forms were prepared using the eight drug layers (DLs) and six expandable layers (SLs) shown in Tables 6 and 7. The tablet cores were coated with coating layers containing CA and PEG, as shown in Table 8. The drug layer compositions and expandable layer compositions are shown in Tables 9 and 10. [Table 6]. Drug Layers (DLs) 1-8 DL APR: HPMCAS PEO 200 kDa magnesium stearate (IG) magnesium stearate (EG) DL-1 50:50 - - + DL-2 50:50 + - - DL-3 50:50 - + - DL-4 50:50 + + + DL-5 50:50 0 0 0 DL-6 50:50 0 0 0 DL-7 48:52 0 0 0 DL-8 52:48 0 0 0 + 105.0% 105.0% 105.0% - 95.0% 95.0% 95.0% 0 100.0% 100.0% 100.0% [Table 7]. Expandable Layers (SL) 1-6 SL PEO 5000 kDa NaCI Magnesium stearate SL-1 - - + SL-2 + - - SL-3 - + - SL-4 + + + SL-5 0 0 0 SL-6 0 0 0 + 105.0% 105.0% 105.0% - 95.0% 95.0% 95.0% 0 100.0% 100.0% 100.0% Percentage change of excipient addition in 75 mg tablet standard formulations containing DL5-8 and SL5-6 [Table 8]. Tablets 1-14 tablet DL ID SL ID CA: PEG wrapper ratio 1 DL-6 SL-1 80 / 20 2 DL-6 SL-2 80 / 20 3 DL-6 SL-3 80 / 20 4 DL-6 SL-4 80 / 20 5 DL-6 SL-5 80 / 20 6 DL-1 SL-6 80 / 20 7 DL-2 SL-6 80 / 20 8 DL-3 SL-6 80 / 20 9 DL-4 SL-6 80 / 20 10 DL-5 SL-6 80 / 20 11 DL-7 SL-6 80 / 20 12 DL-8 SL-6 80 / 20 13 DL-6 SL-6 81 / 19 14 DL-6 SL-6 79 / 21 *For all tablet cores: DL is 491.8 mg; SL is 245.9 mg; and the tablet core weight is 737.7 mg [Table 9]. Drug layer composition Composition DL5-8 DL1 DL2 DL3 DL4 Element mixture% mg / tab mixture% mg / tab mixture% mg / tab mixture% mg / tab mixture% mg / tab Intragranular APR: HPMCAS 30.50 150.0 30.50 150.0 30.50 150.0 30.50 150.0 30.50 150.0 PEO 200 kDa 64.0 314.75 60.80 299.01 67.20 330.49 60.80 299.01 67.20 330.49 Mannitol (Spray drying) 2.50 12.3 4.28 21.04 0.74 3.62 4.28 21.04 0.71 3.48 magnesium stearate 0.25 1.23 0.24 1.17 0.24 1.17 0.26 1.29 0.26 1.29 Particle exterior cSiO2 (gas phase) 0.50 2.46 0.50 2.46 0.50 2.46 0.50 2.46 0.50 2.46 Mannitol (Spray drying) 2.0 9.84 3.42 16.83 0.59 2.90 3.42 16.83 0.57 2.79 magnesium stearate 0.25 1.23 0.26 1.29 0.24 1.17 0.24 1.17 0.26 1.29 total 100.0 491.8 100.0 491.8 100.0 491.8 100.0 491.8 100.0 491.8 [Table 10]. Composition of expandable layers composition SL5-6 SL1 SL2 SL3 SL4 Element mixture% mg / tab mixture% mg / tab mixture% mg / tab mixture% mg / tab mixture% mg / tab PEO 5000 kDa 64.90 159.59 61.66 151.61 68.15 167.57 61.66 151.61 68.15 167.57 MCC 25.80 63.44 29.45 72.42 23.01 56.58 28.64 70.43 22.10 54.34 NaCl 8.60 21.15 8.17 20.09 8.17 20.09 9.03 22.21 9.03 22.21 Iron oxide red 0.20 0.49 0.20 0.49 0.20 0.49 0.20 0.49 0.20 0.49 magnesium stearate 0.50 1.23 0.53 1.29 0.48 1.17 0.48 1.17 0.53 1.29 total 100.0 245.9 100.0 245.9 100.0 245.9 100.0 245.9 100.0 245.9 method
[0111] The drug layer mixture was prepared using the procedure described herein, including mixing, grinding, and dry granulation using roller pressing. The filling volume was calculated assuming a pre-granulated mixture density of 0.48 g / mL. The mixer speed was determined by keeping the Froude number constant at approximately 0.05 across all scales.
[0112] For the premixing of the drug layer, the following components were added to the mixer: polyethylene oxide (e.g., PolyOx WSR-N80, MW 200 kDa), SDD, and mannitol were mixed. The premix was then mixed at low speed by a conical mill. A lubricant (e.g., magnesium stearate) was sieved (20 mesh), added to the mixer, and mixed. The mixture was then granulated using a roller press (parameters see Table 11). The resulting granules were discharged into a container. An excipient (e.g., colloidal silica and mannitol) was added to the mixer and mixed. The excipient mixture was then passed through a conical mill at low speed. The granules and the sieved excipient mixture were then combined and mixed in the mixer. A lubricant (e.g., magnesium stearate) was sieved (20 mesh) and added to the mixer under mixing conditions. The drug layer was discharged after mixing.
[0113] An expandable layer is prepared using a similar procedure, assuming a bulk density of 0.41 g / mL to calculate the fill volume. A penetrant (e.g., sodium chloride) and a colorant (e.g., iron oxide) are combined and mixed at a low speed. The sodium chloride and iron oxide mixture is then passed through a conical mill at a low speed. An expandable polymer (e.g., polyethylene oxide) and a diluent (e.g., microcrystalline cellulose) are added to the sieved mixture and mixed. The combined, mixed mixture is ground and mixed again. A lubricant (e.g., magnesium stearate) is sieved (20 mesh), added to the mixer, and mixed. The mixed expandable layer mixture is discharged.
[0114] Use the process parameters listed in Table 11 for rolling, where the target solids fraction is 0.65, within the range of 0.60-0.70. [Table 11]. Rolling parameters parameter set up Roller settings Main roller (lower left position) Knurled Secondary roller (top right position) Knurled Compression 2.0 kN / cm Pressure roller start speed 0.5 rpm Roller speed 4 (± 1) rpm Gap width 2 (± 0.5) mm PID 3 : 8000 : 0 (No unit: milliseconds : milliseconds) Feed coefficient 0.7 density ratio 0.7 Feed settings Mixer speed (rpm) 5 Compaction / Feed Ratio 300% Gap control activation (on / off) open Torque control (on / off) close Granulator settings Granulator Types star rotor Granulator sieve type Square wire mesh Granulator screen size 1.0 mm Granulator rotor clearance 1.0 mm (0.7-1.1 mm) Granulator speed 60 rpm Granulator CW / CCW degree 360 / 400
[0115] The fraction of banded solids in each drug layer mixture is in the range of 0.62–0.65. Particle size was measured using sieve analysis for each drug layer mixture. Granulation of all drug layers using the same processing parameters (roller speed = 4.0 RPM, roller force = 2.0 kN / cm, roller gap = 2.0 mm, sieve size = 1.0 mm) resulted in a similar particle size distribution. The average particle size is typically between 75–850 µm, with particle sizes in the following ranges: for example, 75–106 µm (less than 5% mass fraction), 106–150 µm (approximately 10% mass fraction), 150–250 µm (approximately 15% mass fraction), 250–500 µm (approximately 30% mass fraction), and 500–850 µm (approximately 37% mass fraction). Bilayer tableting.
[0116] The final mixture was compressed into 14 tablet batches using a Korsch XM12 tablet press. Process parameters are summarized in Table 12. Four 12.0 mm SRC tool stations were used to achieve a processing time of 10–20 minutes for each formulation. All 14 tablet batches were successfully produced, with average tablet weight, thickness, and hardness ranging from 733.8–739.9 mg, 7.10–7.16 mm, and 14.0–16.3 kPa, respectively. The average tablet weight, thickness, and hardness are within acceptable ranges. [Table 12]. Tablet compression parameters for bilayer tablets on the Korsch XM12. parameter value Tableting mode (single-layer / double-layer) Dual-layer mode Tool size 12.00 mm SRC (.4724") DIA. STD CUP Tool drawing number 91558 Number of workstations 4 Turret speed 30 rpm Drug layer weight 491.8 mg Expandable layer weight 245.9 mg Core weight 737.7 mg Filling Cam [10 mm] or as needed First-level feed rack paddle type Standard square paddle First layer feed rack paddle speed 65 rpm (adjust speed as needed; CW rotation) Drug layer delivery depth 8.00 mm Drug layer insertion depth 3.00 mm Drug layer edge depth 4.83 mm Second-layer feed rack paddle type 45° single-slope propeller (Korsch part number 80700345) Second-layer feed rack paddle speed 55 rpm (adjust speed as needed; CW rotation) Depth of administration of expandable layer 6.00 mm Pre-pressing edge thickness 4.83 mm (without pre-compression) Main blank holder thickness 4.23 mm Tablet hardness 15 kP Strengthening the drug layer [1000 N] (Adjust as needed - average compaction force not exceeding 1.3 kN) Precompression force 380 N Compression 8.0 kN Approximate tablet thickness 7.2 mm (7.0-7.2 mm) dust collector yes Coating layer
[0117] Coat the cores 1-14 with one of the coating compositions AC shown in Table 13. The coating conditions are summarized in 14.
[0118] Tablet cores 1-12 are coated with coating composition A, tablet core 13 is coated with coating composition B, and tablet core 14 is coated with coating composition C. The target wet weight gain of the coating is 7.5%. [Table 13]. Coating composition AC Ingredients (%w / w) Coating components A Coating components B Coating components C CA 4.00 4.05 3.95 PEG 3350 1.00 0.95 1.05 acetone 91 91 91 Purified water 4 4 4 [Table 14]. Coating parameters of CA / PEG coating for APR SCT cores 1-14 method Process parameters Target Tablet preheating air velocity 40 CFM T in 45°C T out 35°C Pot speed 3 rpm jog (Press for 5 seconds to turn on, 30 seconds to turn off) CA / PEG coating air velocity 40 CFM T out 35°C Atomizing air pressure 10 psi Patterned air pressure 5 psi Spray solution feed rate per nozzle 20 g / min Pot speed 22 rpm (1.3 L pot) Gun to bed distance C 2.5 in PLC temperature control Entrance Weight gain from wet coating 7.5 wt% Inching drying air velocity 40 CFM T out 35°C T in 45°C Pot speed 3 rpm jog (Press for 5 seconds to turn on, 30 seconds to turn off)
[0119] The coated tablets were perforated using a Stage 1 laser drill with 1.2 mm pores to provide drug release pores, and then dried in a pan for approximately 15 hours. Dissolution studies
[0120] Tablets 6-10 (n = 6) were dissolved, each tablet having a different drug layer (DL 1-5) and the same expandable layer (SL-6). Variations in composition and dissolution parameters of these formulations are presented in Table 15. Dissolution profiles of these formulations are shown in Figure 1. No significant differences in dissolution were observed among the five formulations. The tablets provided suitable dissolution profiles. [Table 15]. Dissolution of Tablets 6-10 tablet 1 DL PEO 200 kDa magnesium stearate (IG) magnesium stearate (EG) RR 2 t 50 (h) dose deliver In 8 h (%) Residual (%) t lag (h) 6 DL-1 - - + 5.3 8.2 49.3 23.2 1.0 7 DL-2 + - - 6.0 9.5 41.1 22.8 1.2 8 DL-3 - + - 5.7 9.0 44.7 25.0 1.2 9 DL-4 + + + 5.7 7.9 50.8 22.3 1.0 10 DL-5 0 0 0 6.1 8.2 48.6 23.7 1.2 + 105% 105% 105% - 95% 95% 95% 0 0 0 0 1. All tablets prepared using the expandable layer SL-6 2. Zero-order release rate (RR) (5–10 h)
[0121] Tablets 1-5 were dissolved (n = 6), each tablet having a different expandable layer (SL 1-5) and the same drug layer (DL-6). Variations in excipient dosage and key dissolution parameters are presented in Table 16. Dissolution profiles are shown in Figure 2. No significant differences were observed in the dissolution profiles of the five formulations. The tablets provided suitable dissolution profiles. [Table 16]. Dissolution of Tablets 1-5 tablet 1 SL PEO 5000 kDa magnesium stearate (IG) magnesium stearate (EG) RR 2 t 50 (h) dose deliver In 8 h (%) Residual (%) t lag (h) 1 SL-1 - - + 6.2 9.5 40.9 20.4 1.4 2 SL-2 + - - 6.5 9.3 41.9 22.0 1.3 3 SL-3 - + - 6.3 8.5 46.7 22.9 1.3 4 SL-4 + + + 6.3 8.5 47.4 21.9 1.2 5 SL-5 0 0 0 6.3 8.8 45.1 23.3 1.3 + 105% 105% 105% - 95% 95% 95% 0 0 0 0 1. All tablets prepared using DL-6 drug layer 2. Zero-order release rate (RR) (5-10 h)
[0122] By varying the ratio of cellulose acetate to polyethylene glycol (PEG 3350), tablet 5 was coated with three different coating solution compositions to provide tablets 5, 5A, and 5B. The specific ratios tested and key dissolution indicators can be found in Table 17. Dissolution curves are shown in Figure 3. No differences were observed in the dissolution curves of the three formulations. [Table 17]. CA / PEG Coating of Tablet 5 tablet DL SL CA: PEG ratio RR 1 t 50 (h) dose deliver In 8 h (%) Residual (%) t lag (h) 5A DL-6 SL-5 81:19 5.5 7.7 52.2 21.2 1.0 5 DL-6 SL-5 80:20 6.3 8.8 45.1 23.3 1.3 5B DL-6 SL-5 79:21 5.6 7.8 51.4 21.2 1.1 1. Zero-order release rate (RR) (5-10 h)
[0123] Tablets 10-12 were formulated with SDDs containing different amounts of apremilast and HPMCAS-L, as shown in Table 18, which also includes key dissolution parameters from the study. Dissolution profiles are presented in Figure 4. Formulations containing an increased amount of apremilast (52%) were observed to have slower release profiles and slightly increased residues compared to the centerline SDD (50% apremilast). For this analysis, the per-tablet dose of these formulations was not normalized to the actual dose found in their respective SDD batches, but rather assumed to be the centerline dose. [Table 18]. Dissolution Results for Tablets 10-12 tablet DL SL APR: HPMCAS-L Ratio in SDD RR 1 t 50 (h) dose deliver In 8 h (%) Residue (%) t lag (h) 10 DL-5 SL-6 50:50 6.1 8.2 48.6 23.7 1.2 11 DL-7 SL-6 48:52 5.4 8.8 46.1 23.6 1.0 12 DL-8 SL-6 52:48 4.9 10.8 39.9 26.2 1.3 1. Zero-order release rate (RR) (5-10 h) Example 3
[0124] This example illustrates an oral dosage form according to an embodiment of the present disclosure.
[0125] Eight tablets (tablets 15-22) were prepared as described herein, comprising the components listed in Table 19. The drug layer of each tablet comprises apremilast and HPMCAS in a weight ratio of 50:50. Furthermore, the drug layer of tablet 15 further comprises extragranular mannitol as a diluent. Additionally, dosage forms 21 and 22 further comprise a base coat containing hydroxypropyl methylcellulose. [Table 19]. Tablets 15-22 tablet 15 16 17 18 19 20 twenty one twenty two Components (mg / tablet) Drug layer Intragranular Aprepitant (mg) 75.0 60.0 60.0 65.0 65.0 70.0 75.0 75.0 HPMCAS (mg) 75.0 60.0 60.0 65.0 65.0 70.0 75.0 75.0 PEO 200 kDa (mg) 314.8 307.2 307.2 332.8 332.8 358.4 314.8 314.8 Mannitol (mg) 12.3 48.0 48.0 52.0 52.0 56.0 22.1 22.1 Magnesium stearate (mg) 1.2 1.2 1.2 1.3 1.3 1.4 1.2 1.2 Particle exterior cSiO2 (mg) 2.5 2.4 2.4 2.6 2.6 2.8 2.5 2.5 Mannitol (mg) 9.8 --- --- --- --- --- --- --- Magnesium stearate (mg) 1.2 1.2 1.2 1.3 1.3 1.4 1.2 1.2 Expandable layer PEO 5000 kDa (mg) 159.6 155.8 155.8 168.7 168.7 181.7 159.6 159.6 MCC (mg) 63.4 61.9 61.9 67.1 67.1 72.3 63.4 63.4 NaCl (mg) 21.1 20.6 20.6 22.4 22.4 24.1 21.1 21.1 Iron oxide red (mg) 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 Magnesium stearate (mg) 1.2 1.2 1.2 1.3 1.3 1.4 1.2 1.2 Chip Total weight (mg) 737.7 720.0 720.0 780.0 780.0 840.0 737.7 737.7 Coating layer HPMC (mg) --- --- --- --- --- --- 18.4 18.4 Purified water* --- --- --- --- --- --- --- --- Film-coated tablets Total weight (mg) --- --- --- --- --- --- 756.1 756.1 CA (mg) 41.3 37.4 72.0 37.4 74.9 40.3 36.3 49.6 PEG (mg) 10.3 9.4 18.0 9.4 18.7 10.1 9.1 12.4 acetone* --- --- --- --- --- --- --- --- Purified water* --- --- --- --- --- --- --- --- CA Coated Tablets Total weight (mg) 789.2 766.8 810 826.8 873.6 890.4 756.1 756.1 Opadry Pink (mg) 27.6 --- --- --- --- --- --- --- Purified water* --- --- --- --- --- --- --- --- Total weight of tablets (mg) 816.8 766.8 810 826.8 873.6 890.4 801.5 818.1 *Removed during processing
[0126] Subjects took one of tablets 16-22 while eating (e.g., 30 minutes after consuming a moderate or high-fat meal). [Table 20]. Tablets 16-22 tablet Drug loading (SDD 1 )% Coating content (CA : PEG)% relatively AUC∞ (%) 1 relatively C max (%) 2 Single-day administration (fasting required) 16 16.7 6.5 77.4 93.2 17 16.7 12.5 66.1 68.7 18 16.7 6.0 90.1 91.4 19 16.7 12.0 58.8 64.3 20 16.7 6.0 73.1 99.3 twenty one 20.3 6.1 66.6 91.7 twenty two 20.3 8.4 80.2 91.6 Single-day administration (standard diet) twenty one 20.3 6.1 94 3 108.9 Multiple doses over 14 days (moderate-fat diet) 20 16.7 6.0 80.2 3 89.8 twenty one 20.3 6.1 88.8 3 93.4 twenty two 20.3 8.4 125.3 3 127.4 1. SDD: APR: HPMCAS 1:1 2. Ratio of adjusted geometric mean (%) (Test / IR BID) 3. AUC0-24 Example 4
[0127] This example illustrates an oral dosage form according to an embodiment of the present disclosure.
[0128] Two 75 mg SCT QD apremilast tablets (tablet A and tablet B) of formulation 15 were prepared. Tablet A (treatment A) and tablet B (treatment B) were administered to subjects during the study period. Treatment was administered with approximately 240 mL (or 8 oz) of non-carbonated room temperature water. Subjects fasted overnight for at least 10 hours before each dose and fasted for at least 4 hours after morning administration. No food or beverages (excluding water) were permitted for at least 4 hours after administration. Water was permitted as needed, except for 1 hour before and 1 hour after administration.
[0129] Blood samples were collected at specific time points for pharmacokinetic (PK) and clinical laboratory assessment. Safety was monitored throughout the study. The mean (± SD) apremilast plasma concentration versus time curve is presented in Figure 5. All pharmacokinetic estimates were calculated using the actual recorded blood collection times. The plasma pharmacokinetic parameters for treatment are summarized in Table 21. [Table 21]. Geometric mean (geometric CV%) estimates of apremilast PK parameters parameter Treatment A Treatment B AUC 0-t (h*ng / mL) 6040 (53.5) 5650 (55.2) AUC 0-∞ (h*ng / mL) 6080 (53.5) 5680 (55.2) C max (ng / mL) 382 (28.1) 357 (28.2) t 1 / 2 (h) 7.2 (29.7) 7.0 (25.6) T max (h) a 6.0 (3.0 - 14.0) 8.0 (3.0 - 14.0) t lag (h) a 0.50 (0.00, 1.00) 0.50 (0.50, 1.00) CL / F (L / h) 12.3 (53.5) 13.2 (55.2) V z / F(L) 128 (49.8) 134 (47.4)
[0130] Following a single oral dose of 75 mg apremilast SCT formulation (treatment A or treatment B), apremilast was slowly absorbed, with maximum plasma concentrations occurring at the median time of reaching maximum plasma concentration (Tmax) at approximately 6 hours and 8 hours, respectively. Exposure in treatment B was slightly lower but considered comparable to that observed in treatment A (Tmax: 357 ng / mL vs. 382 ng / mL, AUC0-t: 5650 h*ng / mL vs. 6040 h*ng / mL, and AUC0-∞: 5680 h*ng / mL vs. 6080 h*ng / mL). After reaching Cmax, apremilast concentrations decreased in both treatments A and B, with a terminal elimination half-life (t1 / 2) of approximately 7 hours. Example 5
[0131] This example illustrates an oral dosage form according to an embodiment of the present disclosure.
[0132] During the study period, subjects took tablet 21 once daily and compared it with 30 mg IR apremilast formulation and 75 mg gastric retention (GR) formulation. Treatment was administered with approximately 240 mL (or 8 oz) of non-carbonated room temperature water. On the day of administration, subjects fasted for at least 8 hours before breakfast and at least 4 hours after morning administration. During the fasting period, subjects were permitted to drink water freely except 1 hour before and 1 hour after administration (excluding any water administered via IP). A standard meal was consumed 30 minutes before morning administration. The standard meal contained approximately 450 calories, of which 25% came from fat. The standard meal was equivalent to 8 oz of 1% skim milk, one large hard-boiled egg, two slices of whole-wheat toast, a small piece of butter (5 g), and one medium-sized banana. The content (regarding calories, fat, protein, and carbohydrates) and timing of lunch, dinner, and all snacks were consistent throughout all days of administration. Lunch, dinner, and snacks were provided approximately 4, 9, and 13 hours after morning administration, respectively.
[0133] Blood samples were collected at specific time points for pharmacokinetic (PK) and clinical laboratory assessment. Safety was monitored throughout the study. The mean (± SD) aprestin plasma concentrations versus time on days 1 and 5 are presented in Figures 6 and 7, respectively. All pharmacokinetic estimates were calculated using the actual recorded blood collection times. Plasma pharmacokinetic parameters for all subjects who completed treatment are presented and summarized in Table 22. [Table 22]. Geometric mean (geometric CV%) estimates of aprestin pharmacokinetic parameters sky parameter 30 mg IR BID Tablet 21 75 mg GR tablets Day 1 AUC 0-24 (ng•h / mL) 4090 (26.9) 4190 (30.2) 3620 (27.4) AUC 0-t (ng•h / mL) 4080 (26.9) 4180 (30.1) 3610 (27.4) C max (ng / mL) 351 (28.4) 358 (27.6) 406 (31.2) T max (h) a 3.00 (2.00, 5.00) 6.00 (4.00, 11.80) 6.00 (4.00, 11.80) t lag (h) 0.5 (0.0) 0.89 (46.8) 0.58 (28.3) Day 5 AUC 0-24 (ng•h / mL) 5040 (29.9) 5110 (34.1) 4010 (33.1) AUC 0-t (ng•h / mL) 6150(31.7) 5980 (38.1) 5270 (40.5) AUC 0-∞ (ng·h / mL) 6210 (31.2) 6020 (38.2) 5410 (42.8) C max (ng / mL) 436 (24.9) 398 (30.9) 448 (36.4) T max (h) a 2.00(1.00,5.00) 6.00 (3.02, 8.00) 6.00(3.00,24.00) t lag (h) b THEN THEN THEN t 1 / 2 (h) 8.11 (28.6) 7.13(32.0) 10.4(48.8) CL / F(L / h) 11.0(26.8) 14.7 (34.1) 18.7 (33.1) V z / F(L) 129 (38.6) 151 (30.9) 280 (47.4) F rel1 (%) THEN 96.9(17.2) 87.2 (36.1) F rel2 (%) THEN 77.5(17.2) 69.8(36.1) RA 1.23(11.0) 1.22 (21.0) 1.11 (36.7)
[0134] When tablet 21 was administered orally as a single or multiple doses once daily, apremilast was slowly absorbed, with the maximum plasma concentration occurring at the median time to reach the maximum plasma concentration (Tmax) at approximately 6 hours (Figures 6, 7, and Table 22). On day 1, the peak plasma concentration (Cmax) of apremilast was similar between tablet 21 and 30 mg IR BID, but the Cmax of tablet 21 was slightly lower on day 5. Compared to 30 mg IR BID (2 hours after administration), tablet 21 showed a delayed median time to reach Cmax, and the Cmax was relatively lower based on the 75 mg daily dose, reflecting the sustained-release effect typical of extended-release formulations (Figures 6, 7, and Table 22).
[0135] Following administration of tablet 21, after reaching steady-state Cmax on day 5, aprestin concentrations decreased, with a terminal elimination half-life (t1 / 2) of approximately 7 hours. In healthy male subjects, after multiple dosings, the aprestin t1 / 2 was similar between tablet 21 and 30 mg IR BID. After single and multiple oral dosings, AUC0-24, AUC0-t, and AUC0-∞ were similar between tablet 21 and 30 mg IR BID. After multiple oral dosings, the accumulation rate of tablet 21 was also similar to that of 30 mg IR BID. The Ctrough on day 5 after oral administration of tablet 21 was lower than that of 30 mg IR BID. The relative bioavailability was comparable between tablet 21 and 30 mg IR BID, but the dose-normalized relative bioavailability of tablet 21 was approximately 23% lower than that of 30 mg IR BID.
[0136] When 75 mg GR tablets were administered orally as a single or multiple doses, apremilast was slowly absorbed, with the maximum plasma concentration occurring at a median time of approximately 6 hours (Tmax) (Figures 6, 7, and Table 22). The peak plasma concentration (Cmax) of apremilast in the 75 mg GR tablets was higher than the Cmax of the IR (instantaneous irradiation). Compared to the IR (2 hours after administration), the 75 mg GR tablets showed a delayed median time to reach Cmax, and the Cmax was relatively low based on the 75 mg daily dose, reflecting the sustained-release effect typical of extended-release formulations (Figures 6, 7, and Table 22).
[0137] Following administration of 75 mg GR tablets, after reaching steady-state Cmax on day 5, aprestin concentrations decreased, with a terminal elimination half-life (t1 / 2) of approximately 10 hours. In healthy male subjects, after multiple dosings, the aprestin t1 / 2 of 75 mg GR tablets was 2 to 3 hours longer than that of 30 mg IR BID. Following single and multiple oral dosings, the AUC0-24, AUC0-t, and AUC0-∞ of 75 mg GR tablets were generally lower than those of 30 mg IR BID. After multiple oral dosings, the accumulation rate and day 5 Ctrough of 75 mg GR tablets were lower than those of 30 mg IR BID (Table 22). The relative bioavailability and dose-normalized relative bioavailability of 75 mg GR tablets were both lower than those of 30 mg IR BID.
[0138] The statistical analysis results of AUC0-24, Cmax, and Ctrough of bioavailability for 21 tablets of apremilast QD (test) and 75 mg GR tablets of apremilast QD (test) relative to 30 mg IR BID apremilast formulation (reference) are summarized in Table 23. The analysis of the difference in median Tmax between day 1 and day 5 is summarized in Table 24. [Table 23]. Comparison of apremilast PK parameters related to post-exposure of 21 tablets and GR tablets. parameter treat geometry average value Compare geometry average value of ratio(%) Geometric Mean ratio 90% CI (%) Subjects Inside Variability CV% AUC 0-24 (ng•h / mL) Tablet 21 5068.4 21 vs IR GR vs IR 100.8 78.6 (90.2, 112.6) (70.3, 87.9) 19.8 GR 3953.5 IR 5029.0 C max (ng / mL) Tablet 21 399.4 21 vs IR GR vs IR 91.4 102.7 (78.2, 106.8) (87.9, 120.1) 28.1 GR 448.9 IR 437.0 C trough (ng / mL) Tablet 21 81.0 21 vs IR GR vs IR 64.1 60.0 (52.1, 78.9) (48.7, 74.0) 38.0 GR 75.8 IR 126.3 [Table 24]. Comparison of Tmax between tablet 21 and GR tablets. sky parameter treat Median Compare Median difference Median Differences 90% CI p-value 1 T max (h) Tablet 21 6.02 B vs A 3.50 (2.01, 4.50) < 0.0001 GR 6.00 C vs A 2.50 (2.00, 3.50) < 0.0001 IR 3.00 5 T max (h) Tablet 21 6.00 B vs A 3.00 (2.50, 4.00) < 0.0001 GR 5.00 C vs A 2.50 (2.00, 3.50) < 0.0001 IR 2.50
[0139] After 5 days of once-daily multiple-dose oral administration of tablets 21 and GR, the AUC0-24 values on day 5 were approximately 100% and 79% of the reference AUC0-24 values, respectively. The Cmax on day 5 for tablets 21 and GR were 91% and 103% of the reference formulation IR 30 mg BID, respectively (Table 23).
[0140] Since the 90% CI of the geometric mean ratio of AUC0-24 shown in Table 23 is in the range of 80% to 125% (standard bioequivalence criteria), the AUC0-24 of the 21 mg apremilast QD formulation and the 30 mg IR apremilast BID formulation are considered comparable, although Cmax and Ctrough are approximately 9% and 36% lower, respectively.
[0141] The AUC0-24 of the GR tablets is approximately 21% lower than that of the 30 mg IR BID. However, since the 90% CI of the geometric mean ratio of Cmax shown in Table 23 is in the range of 80% to 125% (standard bioequivalence criteria), the Cmax of the 75 mg GR tablet apremilast QD formulation and the 30 mg IR apremilast BID formulation are considered comparable. The Ctrough of the GR tablets is approximately 40% lower than that of the 30 mg IR BID.
[0142] Median Tmax analysis is shown in Table 24. The median Tmax of both the 21 mg Aprepitant QD tablet formulation and the 75 mg GR Aprepitant QD tablet formulation was significantly delayed compared to the 30 mg IR Aprepitant BID formulation, with median differences ranging from 2.5 hours to 3 hours. The difference in median Tmax between the two test formulations was statistically significant compared to the reference formulation (p < 0.0001). Example 6
[0143] This example illustrates the tablet formulations and oral dosage forms of embodiments of this disclosure. Tablet formulations 6-1 to 6-13 were prepared, comprising the components listed in Table 25. [Table 25]. Tablet core formulations and oral dosage forms of this disclosure. tablet 6-1 6-2 6-3 6-4 6-5 6-6 6-7 6-8 6-9 6-10 6-11 6-12 6-13 Components (mg / tablet) Drug layer Intragranular Apst 100 100 75 75 75 75 55 55 27.5 27.5 75 55 27.5 HPMCAS 100 100 75 75 75 75 55 55 27.5 27.5 75 55 27.5 PEO (300 kDa) 150.7 274.6 113 206 274.6 274.6 82.9 151.1 41.4 75.5 --- --- --- PEO (200 kDa) 150.7 --- 113 --- --- --- 82.9 --- 41.4 --- 314.8 230.9 115.6 NaCl 26.7 53.3 20 40 40 40 14.7 29.3 7.3 14.7 --- --- --- Mannitol --- --- --- --- --- 25 --- --- --- --- 12.3 9 4.5 magnesium stearate 1.3 1.3 1 1 1 1 0.7 0.7 0.4 0.4 1.2 0.9 0.5 Particle exterior cSiO2 2.7 2.7 2 2 2 2 1.5 1.5 0.7 0.7 2.5 1.8 0.9 Mannitol --- --- --- --- 50 25 --- --- --- --- 9.8 7.2 3.6 magnesium stearate 1.3 1.3 1 1 1 1 0.7 0.7 0.4 0.4 1.2 0.8 0.5 Expandable layer PEO (5000 kDa) 173.1 173.1 129.8 129.8 173.1 173.1 95.2 95.2 47.6 47.6 159.6 117 58.6 MCC 68.8 68.8 51.6 51.6 68.8 68.8 37.8 37.8 18.9 18.9 63.4 46.5 23.3 NaCl 22.9 22.9 17.2 17.2 22.9 22.9 12.6 12.6 6.3 6.3 21.1 15.5 7.8 Iron oxide red 0.5 0.5 0.4 0.4 0.5 0.5 0.3 0.3 0.1 0.1 0.5 0.4 0.2 magnesium stearate 1.3 1.3 1 1 1.3 1.3 0.7 0.7 0.4 0.4 1.2 0.9 0.5 Chip 800.0 799.8 600.0 600.0 785.2 785.2 440.0 439.9 219.9 220.0 737.6 540.9 271.0 Coating layer CA 41.6 37.8 36.0 36.0 47.1 47.1 26.4 26.4 13.2 13.2 41.3 30.3 15.2 PEG 10.4 9.4 9.0 9.0 11.8 11.8 6.6 6.6 3.3 3.3 10.3 7.6 3.8 acetone* --- --- --- --- --- --- --- --- --- --- --- --- --- Purified water* --- --- --- --- --- --- --- --- --- --- --- --- --- CA Coated Tablets 852.0 847.0 645.0 645.0 844.1 844.1 473.0 472.9 236.4 236.5 789.2 578.8 290.0 Total weight (mg) Oppa fan --- --- --- --- --- --- --- --- --- --- 27.6 20.2 10.1 Purified water* --- --- --- --- --- --- --- --- --- --- --- --- --- Total weight of tablets (mg) 852.0 847.0 645.0 645.0 844.1 844.1 473.0 472.9 236.4 236.5 816.8 599.0 300.1 Example 7
[0144] This example illustrates a 100 mg tablet core formulation of this disclosed embodiment. 100 mg tablet core formulations 7-1 to 7-6 were prepared, comprising the drug layer components listed in Table 26. Each of 7-1 to 7-6 comprises the same expandable layer containing the following components (wt% of expandable layer): 64.9% PEO, 25.8% MCC, 8.6% NaCl, 0.2% iron oxide red; and 0.5% magnesium stearate. The total weight of each drug layer in 7-1 to 7-6 is 533.3 mg, and the weight of the expandable layer is 266.7 mg, such that the total uncoated weight of each tablet core composition is 800 mg. [Table 26]. Tablet core compositions 7-1 to 7-6 (100 mg) Chip Composition 7-1 7-2 7-3 7-4 7-5 7-6 Drug layer Components Particle size (mixture %) 50% APM: HPMCAS-L SDD 37.5 37.5 37.5 37.5 37.5 37.5 PEO (200 kDa) 61.50 30.75 --- 51.50 25.75 --- PEO (600 kDa) --- 30.75 61.50 --- 25.75 51.50 NaCl --- --- --- 10.0 10.0 10.0 magnesium stearate 0.25 0.25 0.25 0.25 0.25 0.25 Components Outside of particles (mixture %) cSiO2 0.50 0.50 0.50 0.50 0.50 0.50 magnesium stearate 0.25 0.25 0.25 0.25 0.25 0.25
[0145] The dissolution of tablet core formulations 7-1 to 7-6 was analyzed under the following conditions: Instrument used: USP device 2 (paddle); Container: 1 L dissolution container with low evaporation cap; Paddle stirring speed: 75 ± 2 rpm; Dissolution medium temperature: 37.0 ± 0.5°C; Sample volume: one tablet per container; Dissolution medium composition: 0.5% Tween® 80 in sodium acetate buffer, pH 5.5; Dissolution medium volume: 900 mL; Sample volume: 1.5 mL (automatic sampler) or 5 mL (manual sampling).
[0146] The results are shown in Table 27 and Figure 8. [Table 27]. Dissolution of the core components described in Table 26 Chip Composition Lag time (h) Residual (%) t 70 (h) Level 0 RR (% / h) 1 7-1 1.0 38 NA 3.8 7-2 2.4 twenty two 19.5 4.9 7-3 4.3 33 NA 4.5 7-4 0.4 59 NA 2.2 7-5 2.2 19 9.8 9.3 7-6 3.4 12 11.3 9.5 1. The calculated release rate is between 5 and 10 hours.
[0147] As shown in Table 27 and Figure 8, in the presence of a penetrant in the drug layer, the dissolution rate at 24 h increased with increasing high molecular weight PEO fraction. Furthermore, the hysteresis time increased with increasing MW of PEO and was shorter in the presence of a penetrant in the drug layer. With increasing high molecular weight PEO (600 kDa) fraction and penetrant (e.g., NaCl), core composition 7-4 had the highest residual aprestinate balance, while core compositions 7-5 and 7-6 had decreased residual aprestinate balances. Overall, the dissolution performance of formulations with high MW PWO was improved in the presence of a penetrant (7-2 compared to 7-5 and 7-3 compared to 7-6).
[0148] Next, tablet core compositions 7-7 to 7-12 were prepared, comprising the drug layer shown in Table 28 and the same expandable layer as described above. [Table 28]. Tablet core compositions 7-7 to 7-12 (100 mg) Chip Composition 7-7 7-8 7-9 7-10 7-11 7-12 Drug layer Components Particle size (mixture %) 50% APM: HPMCAS-L SDD 37.5 37.5 37.5 37.5 37.5 37.5 PEO (300 kDa) 30.75 28.25 25.75 61.50 56.50 51.50 PEO (200 kDa) 30.75 28.25 25.75 --- --- --- NaCl --- 5.0 10.0 --- 5.0 10.0 magnesium stearate 0.25 0.25 0.25 0.25 0.25 0.25 Components Outside of particles (mixture %) cSiO2 0.50 0.50 0.50 0.50 0.50 0.50 magnesium stearate 0.25 0.25 0.25 0.25 0.25 0.25
[0149] The dissolution of compositions 7-7 to 7-12 was evaluated using the same conditions as described above.
[0150] The results are shown in Table 29 and Figure 9. [Table 29]. Dissolution of the core components described in Table 28 Chip Composition Lag time (h) Residual (%) t 70 (h) Level 0 RR (% / h) 1 7-7 1.4 16 15.2 5.8 7-8 1.9 19 11.5 7.5 7-9 2 27 13.7 7.0 7-10 2.9 20 17.7 5.2 7-11 2.7 14 11.0 7.6 7-12 1.9 14 10.3 8.3 1. The calculated release rate is between 5 and 10 hours.
[0151] As shown in Table 29 and Figure 9, for compositions 7-7 to 7-9 containing a mixture of two PEO grades, both hysteresis time and residual aprestin % increased with increasing penetrant concentration in the drug layer. For compositions with high MW PEO (7-10 to 7-12), hysteresis time and residual aprestin decreased or remained constant with increasing penetrant concentration. Composition 7-12 exhibited ideal performance with the lowest amount of residual aprestin and short hysteresis time when containing a single grade of PEO and 10% NaCl.
[0152] Generally, the minimization of residues during dissolution is influenced by the sodium chloride concentration and the molecular weight of PEO in the drug layer, with the lowest residues found in formulations containing 10% sodium chloride and the highest MW PEO (PolyOx WSR 205, MW = 600 kDa). For compositions with high MW PEO (7-3 compared to 7-6 and 7-10 to 7-12), increasing the amount of sodium chloride (5% and 10% of the drug layer) reduced lag time and increased release rate. The shortest lag time was observed in formulations with 10% NaCl and the lowest molecular weight PEO (PolyOx WSR N80, MW = 200 kDa). Ideal formulations would use the simplest formulation to reduce residue and lag time; therefore, formulation 7-12 performed best overall in rounds 1 and 2, with a lag time of 1.9 hours and a residue of 14%, using only one grade of PEO (PolyOx WSR N750 LEO) and 10% sodium chloride.
[0153] In the stability study, PXRD analysis showed that core formulation 7-8 exhibited a certain degree of crystallinity and decreased dissolution after 3 and 6 months at 40°C / 75% RH (Figures 10A and 10B). In contrast, core formulation 7-12 showed no change in crystallinity or dissolution after 6 months at 40°C / 75% RH (Figures 11A and 11B). Core formulation 7-8 showed no change after 3 or 6 months at 30°C / 65% RH (Figures 10B and 11B). To ensure the sensitivity of the PXRD method to the stability of crystalline drugs in formulation samples, 0.5% milled API from the SDD standard was used as a control in these measurements (Figures 10B and 11B).
[0154] No changes in dissolution or crystallinity were observed in 7-8 and 7-12 at 25°C / 60% RH and 30°C / 65% RH, while 7-12 remained stable under these conditions. It was determined that undissolved drug in the dissolution medium combined with residues in the tablets, which explains the dose percentage difference in dissolution of samples with decreased performance (for this formulation, approximately 10%–15% of the drug is expected to remain in the tablet shell) (Figure 10A). Acetonitrile (ACN) was added after the 24-hour time point and bath homogenization was performed to ensure complete dissolution of residual drug in the tablets (Figures 10A and 11A).
[0155] These data indicate that, under accelerated stability conditions of 30°C / 65% RH and 40°C / 75% RH, a high MW PEO in the drug layer is beneficial in ensuring adequate solubility. Under these conditions, the presence of NaCl in the drug layer ensures sufficient hysteresis time.
[0156] The foregoing examples are only for illustrating the implementation of the disclosure process described herein and are not intended to limit the disclosed methods. Variations and modifications that will be apparent to those skilled in the art are intended to fall within the scope and nature of this disclosure as defined by the appended claims.
[0157] All references cited herein (including publications, patent applications and patents) are hereby incorporated by reference as if each reference were individually and explicitly indicated to be incorporated by reference and set forth in its entirety herein.
[0158] Unless otherwise indicated herein or the context clearly contradicts, the use of the terms "a / an," "the," and "at least one," and similar indicators in the context of describing embodiments of this disclosure (particularly in the context of the following claims) shall be construed as covering both singular and plural. The use of the term "at least one" followed by a list of one or more items (e.g., "at least one of A and B") shall be interpreted as indicating a selection of one item from the listed items (A or B) or any combination of two or more of the listed items (A and B), unless otherwise stated herein or clearly contradicted by the context. Unless otherwise described, the terms "comprising," "having," "including," and "containing" shall be considered open-ended terms (i.e., meaning "including (but not limited to)"). Unless otherwise indicated herein, statements herein relating to ranges of values are intended only as a way of individually referring to each independent value within that range, and each independent value is incorporated into the specification as if it were individually stated herein. Unless otherwise indicated herein or otherwise obviously contradicted by the context, all methods described herein may be performed in any suitable order. The use of any and all instances or exemplary language (e.g., "for example") provided herein is intended only to better illustrate implementations of this disclosure and not to limit the scope of this disclosure, unless otherwise required. The language in this specification should not be construed as indicating that any unclaimed element is necessary to practice this disclosure. [Simplified Explanation of the Diagram]
[0007] [Figure 1] shows the dissolution curves of tablets 6-10.
[0008] [Figure 2] shows the dissolution curves of tablets 1-5.
[0009] [Figure 3] shows the dissolution curves of uncoated or CA or PEG coated tablet core 5.
[0010] [Figure 4] shows the dissolution curve of tablet 10-12.
[0011] [Figure 5] shows the mean (±SD) apoptosis plasma concentration-time curve.
[0012] [Figure 6] shows the plasma concentration of 75 mg tablet 21 (hollow circle) once a day over 24 hours compared with the 30 mg immediate-release formulation twice a day (solid circle) and the 75 mg gastric-coated (GR) tablet once a day (solid diamond).
[0013] [Figure 7] shows the aprepitant plasma concentrations of 75 mg tablet 21 (hollow circle) once daily over 5 days, compared to the 30 mg immediate-release formulation twice daily (solid circle) and the 75 mg gastric-coated (GR) tablet once daily (solid diamond).
[0014] [Figure 8] shows the dissolution rates of core components 7-1 to 7-6.
[0015] [Figure 9] shows the dissolution rates of the core components 7-7 to 7-12.
[0016] [Figure 10A] shows the decrease in dissolution of core components 7-8 under various storage conditions.
[0017] [Figure 10B] shows the increase in crystallinity of core components 7-8 after various storage conditions.
[0018] [Figure 11A] shows the dissolution of core components 7-12 under various storage conditions.
[0019] [Figure 11B] shows a comparison of the crystallinity of core compositions 7-8 and 7-12 under different storage conditions. [Biomaterial Storage]
[0160] None
Claims
1. An oral dosage form comprising: a. a tablet core comprising (i) a drug layer comprising (a) apremilast and hydroxypropyl methylcellulose acetate succinate (HPMCAS) in an amorphous solid dispersion and (b) a water-soluble polymer comprising polyethylene oxide having an average molecular weight of 200 kDa to 600 kDa; and (ii) an expandable layer comprising polyethylene oxide having an average molecular weight of 5000 kDa and a penetrant; and b. a coating layer disposed on the tablet core, wherein the apremilast and HPMCAS are present in the tablet core in a weight ratio of 45:55 to 55:45, and the oral dosage form surface comprises at least one drug release pore.
2. The oral dosage form of claim 1, wherein the apremilast is present in an amount of 6-15 wt% of the tablet core.
3. The oral dosage form as requested in item 1 or 2, wherein the solid dispersion system is spray-dried.
4. The oral dosage form as requested in item 1, wherein the HPMCAS is present in an amount of 6-15 wt% of the tablet core.
5. The oral dosage form of claim 1, wherein apremilast and HPMCAS are present in the tablet core in a weight ratio of 48:52 to 52:
48.
6. The oral dosage form of claim 1, wherein the drug layer further comprises one or more of a diluent, a penetrant, and a lubricant.
7. The oral dosage form of claim 6, wherein the penetrant comprises sodium chloride.
8. The oral dosage form of claim 1, wherein the polyethylene oxide present in the drug layer has an average molecular weight of 200 kDa.
9. The oral dosage form of claim 1, wherein the water-soluble polymer and apremilast are present in the drug layer in a weight ratio of 2-6:
1.
10. The oral dosage form of claim 1, wherein the drug layer and the expandable layer are present in the tablet core in a weight ratio of 2:
1.
11. The oral dosage form of claim 6, wherein the diluent contains mannitol.
12. An oral dosage form comprising: a. a tablet core comprising (i) a drug layer comprising 8-11 wt% aprestinum, 8-11 wt% hydroxypropyl methylcellulose acetate succinate (HPMCAS) based on the total weight of the tablet core, 2-7 wt% mannitol based on the total weight of the tablet core, 40-45 wt% polyethylene oxide with a molecular weight of 200,000 Da based on the total weight of the tablet core, 0.1-0.5 wt% magnesium stearate based on the total weight of the tablet core, and 0.1-0.5 wt% colloidal silica based on the total weight of the tablet core, wherein the aprestinum and HPMCAs are in a solid dispersion; (ii) an expandable layer comprising 18-25 wt% polyethylene oxide with a molecular weight of 5,000,000 Da based on the total weight of the tablet core, 7-10 wt% mannitol based on the total weight of the tablet core, 8-11 wt% hydroxypropyl methylcellulose acetate succinate (HPMCAS) based on the total weight of the tablet core, 2-7 wt% mannitol based on the total weight of the tablet core, 40-45 wt% polyethylene oxide with a molecular weight of 200,000 Da, 7-10 wt% magnesium stearate based on the total weight of the tablet core, and 0.1-0.5 wt% colloidal silica based on the total weight of the tablet core. a. wt% microcrystalline cellulose, 1.5-3.5 wt% sodium chloride based on the total weight of the tablet core, 0.01-0.2 wt% iron oxide based on the total weight of the tablet core, and 0.05-0.3 wt% magnesium stearate based on the total weight of the tablet core; and b. a coating layer disposed on the tablet core and comprising cellulose acetate and polyethylene glycol; wherein the oral dosage form surface comprises at least one drug release pore.
13. An oral dosage form comprising a tablet core and a coating layer disposed on the tablet core, wherein the surface of the oral dosage form includes at least one drug release pore, and the oral dosage form comprises one of the following: i) a. a tablet core comprising (i) a drug layer comprising 75 mg apremilast, 75 mg hydroxypropyl methylcellulose acetate succinate (HPMCAS), 22.1 mg mannitol, 314.8 mg polyethylene oxide with a molecular weight of 200,000 Da, 2.4 mg magnesium stearate and 2.5 mg colloidal silicon dioxide, wherein the apremilast and HPMCAS are in a solid dispersion; (ii) an expandable layer comprising 159.6 mg polyethylene oxide with a molecular weight of 5,000,000 Da, 63.4 mg microcrystalline cellulose, 21.1 mg sodium chloride, 0.5 mg iron oxide and 1.2 mg magnesium stearate; and b. A coating layer disposed on the tablet core and comprising cellulose acetate and polyethylene glycol; wherein the oral dosage form surface comprises at least one drug release pore; ii) a. a tablet core comprising (i) a drug layer comprising 55 mg aprestinum, 55 mg hydroxypropyl methylcellulose acetate succinate (HPMCAS), 16.2 mg mannitol, 230.9 mg polyethylene oxide with a molecular weight of 200,000 Da, 1.7 mg magnesium stearate and 1.8 mg colloidal silicon dioxide, wherein the aprestinum and HPMCAS are in a solid dispersion; (ii) an expandable layer comprising 117 mg polyethylene oxide with a molecular weight of 5,000,000 Da, 46.5 mg microcrystalline cellulose, 15.5 mg sodium chloride, 0.4 mg iron oxide and 0.9 mg magnesium stearate; and b. A coating layer disposed on the tablet core and comprising cellulose acetate and polyethylene glycol; wherein the oral dosage form surface comprises at least one drug release pore; iii) a. a tablet core comprising (i) a drug layer comprising 27.5 mg apremilast, 27.5 mg hydroxypropyl methylcellulose acetate succinate (HPMCAS), 8.1 mg mannitol, 115.6 mg polyethylene oxide with a molecular weight of 200,000 Da, 1.0 mg magnesium stearate and 0.9 mg colloidal silicon dioxide, wherein the apremilast and HPMCAS are in a solid dispersion; (ii) an expandable layer comprising 58.6 mg polyethylene oxide with a molecular weight of 5,000,000 Da, 23.3 mg microcrystalline cellulose, 7.8 mg sodium chloride, 0.2 mg iron oxide and 0.5 mg magnesium stearate; and b. A coating layer disposed on the tablet core and comprising cellulose acetate and polyethylene glycol; wherein the oral dosage form surface includes at least one drug release pore; iv) a.The tablet core comprises (i) a drug layer comprising 9-15 wt% aprestinum, 10-15 wt% hydroxypropyl methylcellulose succinate (HPMCAS) based on the total weight of the tablet core, 0-27 wt% mannitol based on the total weight of the tablet core, 30-40 wt% polyethylene oxide or a mixture thereof with a molecular weight of 200,000-300,000 Da based on the total weight of the tablet core, 2-8 wt% sodium chloride based on the total weight of the tablet core, 0.1-0.5 wt% magnesium stearate based on the total weight of the tablet core, and 0.1-0.5 wt% colloidal silicon dioxide based on the total weight of the tablet core, wherein the aprestinum and HPMCAs are in a solid dispersion; and (ii) an expandable layer comprising 15-25 wt% polyethylene oxide with a molecular weight of 5,000,000 Da based on the total weight of the tablet core, and 5-10 wt% of [unclear - possibly a specific ingredient or substance] based on the total weight of the tablet core. a. wt% microcrystalline cellulose, 2-4 wt% sodium chloride based on the total weight of the tablet core, 0.01-0.1 wt% iron oxide based on the total weight of the tablet core, and 0.05-0.3 wt% magnesium stearate based on the total weight of the tablet core; and b. a coating layer disposed on the tablet core and comprising cellulose acetate and polyethylene glycol; wherein the oral dosage form surface comprises at least one drug release pore; v) a. a tablet core comprising (i) a drug layer comprising 100 mg aprestinum, 100 mg hydroxypropyl methylcellulose acetate succinate (HPMCAS), 301.4 mg polyethylene oxide or a mixture thereof with a molecular weight of 200,000-300,000 Da, 26.7 mg sodium chloride, 2.6 mg magnesium stearate, and 2.7 mg colloidal silicon dioxide, wherein the aprestinum and HPMCAS are in a solid dispersion; (ii) an expandable layer comprising 173.1 a. a. a 5,000,000 Da polyethylene oxide, 68.8 mg microcrystalline cellulose, 22.9 mg sodium chloride, 0.5 mg iron oxide, and 1.3 mg magnesium stearate; and b. a coating layer disposed on the tablet core and comprising cellulose acetate and polyethylene glycol; wherein the oral dosage form surface comprises at least one drug release pore; vi) a. a tablet core comprising (i) a drug layer comprising 100 mg aprestinum, 100 mg hydroxypropyl methylcellulose acetate succinate (HPMCAS), 274.6 mg 300,000 Da polyethylene oxide, 53.3 mg sodium chloride, 2.6 mg magnesium stearate, and 2.7 mg colloidal silica, wherein the aprestinum and HPMCAS are in a solid dispersion; and (ii) an expandable layer comprising 173.1 mg 5,000,000 Da polyethylene oxide, 68.8 mg microcrystalline cellulose, 22.9 mg sodium chloride, 0.5 mg iron oxide, and 1.3 mg magnesium stearate; and b. a coating layer disposed on the tablet core and comprising cellulose acetate and polyethylene glycol; wherein the oral dosage form surface comprises at least one drug release pore; Da contains polyethylene oxide, 68.8 mg microcrystalline cellulose, 22.9 mg sodium chloride, 0.5 mg iron oxide, and 1.3 mg magnesium stearate; and b. a coating layer disposed on the tablet core and comprising cellulose acetate and polyethylene glycol; wherein the oral dosage form surface comprises at least one drug release pore; vii) a. a tablet core comprising (i) a drug layer comprising 75 mg aprestinum, 75 mg hydroxypropyl methylcellulose succinate (HPMCAS), 226.0 mg polyethylene oxide or a mixture thereof with a molecular weight of 200,000-300,000 Da, 20.0 mg sodium chloride, 2.0 mg magnesium stearate and 2.0 mg colloidal silicon dioxide, wherein the aprestinum and HPMCAS are in a solid dispersion; (ii) an expandable layer comprising 129.8 mg polyethylene oxide with a molecular weight of 5,000,000 Da, 51.6 mg microcrystalline cellulose, 17.2 mg sodium chloride, 0.4 mg iron oxide and 1.0 mg magnesium stearate; and b. A coating layer disposed on the tablet core and comprising cellulose acetate and polyethylene glycol; wherein the oral dosage form surface comprises at least one drug release pore; viii) a. a tablet core comprising (i) a drug layer comprising 75 mg apremilast, 75 mg hydroxypropyl methylcellulose acetate succinate (HPMCAS), 206.0 mg polyethylene oxide with a molecular weight of 300,000 Da, 40.0 mg sodium chloride, 2.0 mg magnesium stearate and 2.0 mg colloidal silicon dioxide, wherein the apremilast and HPMCAS are in a solid dispersion; (ii) an expandable layer comprising 129.8 mg polyethylene oxide with a molecular weight of 5,000,000 Da, 51.6 mg microcrystalline cellulose, 17.2 mg sodium chloride, 0.4 mg iron oxide and 1.0 mg magnesium stearate; and b. A coating layer disposed on the tablet core and comprising cellulose acetate and polyethylene glycol; wherein the oral dosage form surface comprises at least one drug release pore; ix) a. A tablet core comprising (i) a drug layer comprising 55 mg aprestinum, 55 mg hydroxypropyl methylcellulose acetate succinate (HPMCAS), 165.7 mg polyethylene oxide or a mixture thereof with a molecular weight of 200,000-300,000 Da, 14.7 mg sodium chloride, 1.4 mg magnesium stearate and 1.5 mg colloidal silicon dioxide, wherein the aprestinum and HPMCAS are in a solid dispersion; (ii) an expandable layer comprising 95.2 mg polyethylene oxide with a molecular weight of 5,000,000 Da, 37.8 mg microcrystalline cellulose, 12.6 mg sodium chloride, 0.3 mg iron oxide and 0.7 mg magnesium stearate; and b.A coating layer disposed on the tablet core and comprising cellulose acetate and polyethylene glycol; wherein the oral dosage form surface comprises at least one drug release pore; x) a. a tablet core comprising (i) a drug layer comprising 55 mg apremilast, 55 mg hydroxypropyl methylcellulose acetate succinate (HPMCAS), 151.1 mg polyethylene oxide with a molecular weight of 300,000 Da, 29.3 mg sodium chloride, 1.4 mg magnesium stearate and 1.5 mg colloidal silicon dioxide, wherein the apremilast and HPMCAS are in a solid dispersion; (ii) an expandable layer comprising 95.2 mg polyethylene oxide with a molecular weight of 5,000,000 Da, 37.8 mg microcrystalline cellulose, 12.6 mg sodium chloride, 0.3 mg iron oxide and 0.7 mg magnesium stearate; and b. A coating layer disposed on the tablet core and comprising cellulose acetate and polyethylene glycol; wherein the oral dosage form surface comprises at least one drug release pore; xi) a. a tablet core comprising (i) a drug layer comprising 27.5 mg apremilast, 27.5 mg hydroxypropyl methylcellulose acetate succinate (HPMCAS), 82.9 mg polyethylene oxide or a mixture thereof with a molecular weight of 200,000-300,000 Da, 7.3 mg sodium chloride, 0.8 mg magnesium stearate and 0.7 mg colloidal silicon dioxide, wherein the apremilast and HPMCAS are in a solid dispersion; (ii) an expandable layer comprising 47.6 mg polyethylene oxide with a molecular weight of 5,000,000 Da, 18.9 mg microcrystalline cellulose, 6.3 mg sodium chloride, 0.1 mg iron oxide and 0.4 mg magnesium stearate; and b. A coating layer disposed on the tablet core and comprising cellulose acetate and polyethylene glycol; wherein the oral dosage form surface comprises at least one drug release pore; or xii) a. a tablet core comprising (i) a drug layer comprising 27.5 mg apremilast, 27.5 mg hydroxypropyl methylcellulose acetate succinate (HPMCAS), 75.5 mg polyethylene oxide with a molecular weight of 300,000 Da, 14.7 mg sodium chloride, 0.4 mg magnesium stearate and 0.7 mg colloidal silicon dioxide, wherein the apremilast and HPMCAS are in a solid dispersion; (ii) an expandable layer comprising 47.6 mg polyethylene oxide with a molecular weight of 5,000,000 Da, 18.9 mg microcrystalline cellulose, 6.3 mg sodium chloride, 0.1 mg iron oxide and 0.4 mg magnesium stearate; and b. A coating layer is disposed on the tablet core and comprises cellulose acetate and polyethylene glycol; wherein the oral dosage form surface includes at least one drug release pore.
14. Use of an oral dosage form of any one of claims 1-13 for the preparation of a medicament for the treatment of a patient suffering from a disease or disorder that is alleviated by inhibiting PDE4, wherein the treatment comprises administering the medicament to the patient once daily under eating conditions.
15. For the purposes of claim 14, wherein the disease or disorder is psoriasis, psoriatic arthritis or Behcet's disease.
16. As requested in claim 14, wherein the disease or disorder is colitis or inflammatory bowel disease.
Citation Information
Patent Citations
Pharmaceutical compositions for immediate release of drug
CZ20180150A3
